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CHAPTER 1
General introduction
1.1 The evolving concept of Sjögren’s syndrome diagnosis
1.2 Pathogenesis and pathophysiology of Sjögren’s syndrome
1.3 Can disease activity be assessed in Sjögren’s syndrome ?
1.4 Treatment: localized and systemic approaches 
1.5 Aims and outline of the thesis
1.1 - The evolving concept of Sjögren’s syndrome diagnosis
Sjögren’s  syndrome  (SS)  is  considered  a  chronic  autoimmune  exocrinopathy,
particularly involving salivary and lacrimal glands. As a result SS patients experience
so called sicca symptoms such as dry eyes and dry mouth.  In addition, exocrine
glands that are located in the upper airways, the vagina and possibly the skin may
also be affected. SS is thought to affect approximately 0.5-1.0% of the population in
the US and Europe, and has been subject of extensive scientific research. One of the
continuing dilemmas in both research and daily clinical practice however is how to
define SS. As a consequence, data obtained can often not  be easily  compared.
Importantly,  whereas some physicians diagnose SS by using classification criteria
sets, others prefer to establish a diagnosis based on the clinical symptoms and signs
that  constitute  the syndrome. This  paper  deals  with  the evolving concept of  SS,
starting from the early descriptions of the syndrome by Henrik Sjögren and others,
describing the various classification criteria and consecutive modifications that have
been applied  to  them,  and  finishing with  possible  future developments  and their
implications for both research and daily clinical practice.
The early years: 
descriptions of clinical and histopathological features of the syndrome
In medicine a syndrome is defined as a group of symptoms that collectively indicate
or characterize a disease or abnormal condition. Both clinical and histopathological
features of the medical condition nowadays known as  Sjögren’s syndrome have
been  described  over  a  century  ago.  In  1888  the  London  physician  Halden1
described the concurrent  presence of  dry eyes and dry mouth in a  65-year-old
woman also suffering from loss of taste and smell. When she was treated with
tincture of jaborandi (pilocarpine),  her mouth became much more moist. Also in
1888, the polish surgeon Mickulicz2 noticed a combined and similar salivary and
lacrimal  gland  pathology.  He  demonstrated  the  presence  of  a  round  cell
(lymphocytic) infiltration into both the enlarged parotid and lacrimal glands of a 42-
year-old male farmer. Because Mickulicz described histopathological abnormalities
without an explicit association with clinical features, a number of distinct diseases
leading to salivary gland enlargement and lymphocytic infiltration was then labelled
Mickulicz disease. Sixty-five years later Morgan and colleagues concluded that the
patient presented by Mickulicz had in fact the same histopathological features as
then seen in SS patients3. It also took some decades since the first observations by
Halden and Mickulicz, before others not only combined these symptoms and signs
to a syndrome, but also explicitly hypothesised the syndrome to be caused by an
underlying  systemic  disease.  In  an  interview  Henrik  Sjögren,  whose  name  is
currently linked to the syndrome, stated that his major contribution has been the
recognition  of  the  sicca  syndrome  as  a  systemic  disease4.  By  describing
keratoconjunctivitis sicca in patients with chronic polyarthritis the Dutchman Mulock
Houwer5, and the Swedish ophthalmologist Henrik Sjögren6 noted characteristics
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for an underlying systemic disease responsible for the syndrome, whilst the French
physician Gougerot7 presumed a generalized exocrinopathy. Since exocrinopathy is
still considered as a major characteristic of SS, it might have been named after the
French  physician  as  well.  Previously  the  term Gougerot-Sjögren syndrome  has
indeed been used in literature quite often. However, both Sjögren and Gougerot
failed to further specify whether the suggested underlying systemic autoimmune
disease was a specific and distinct disease entity or whether this could be any form
of  previously  known  systemic  disease.  In  other  words:  does  a  distinct
pathophysiological  mechanism  lead  to  SS,  or  can  several  different
pathophysiological mechanisms all lead to SS, which could then be considered as
a final common pathway of multiple systemic diseases? By leaving this issue open
the question how to define SS became an ongoing dilemma. In 1965 Bloch and
Buchanan  postulated  the  definition  that  SS  consists  of  the  triad  of
keratoconjunctivitis sicca (KCS), xerostomia and rheumatoid arthritis (RA) or any
other  connective  tissue  disease8.  This  clinical  definition  has  also  considerably
influenced the continuing debate on the definition of SS. Since two of the three
components  were  sufficient  for  the  diagnosis,  in  clinical  practice  a  rather
heterogeneous group of patients was labelled as having SS.
 
A heterogeneous SS population:  the need for classification criteria
In the years following the work of Sjögren and Gougerot a wide range of symptoms
has been added to the clinical concept of SS. The suggested underlying systemic
disease remained to be further specified. Although objective but non-specific tests,
such as Schirmer’s test, tear drop break-up time or rose bengal cornea staining,
were applied to diagnose KCS, histopathological examination was not frequently
performed yet. In the absence of objective evidence of a specific systemic disease
(e.g. serological or histological markers) sicca syndrome appeared to be equivalent
to Sjögren’s syndrome. Indeed, according to the Bloch definition of  SS, for the
systemic disease component any connective tissue disease would do as long as
the patient had KCS and/or xerostomia. Whether such a designation of Sjögren’s
syndrome  accurately  identified  a  specific  group  of  patients  with  a  common
pathogenesis or prognosis is questionable, as was recognised more recently by
Fox9. Meanwhile continuing research had provided accumulating serological and
histological data suggestive of different underlying pathophysiological mechanisms
within the SS population. Whereas a dense glandular lymphocytic infiltrate, such as
described  by  Mickulicz,  is  present  in  the  majority  of  SS  patients  and  can  be
quantified in a lymphocytic focus score (LFS), in RA patients supposed to have SS
as well, such a histopathological finding is often lacking. Thus, in clinically virtually
undistinguishable sicca syndrome patients distinct  histopathological  features  are
found. Vice versa not all lymphocytic infiltrates necessarily reflect the same medical
disease. E.g. a LFS > 1.0 can be found in SS, but also in other medical conditions
such  as  RA,  SLE,  scleroderma,  graft-versus-host  disease,  AIDS,  myasthenia
gravis, primary biliary cirrhosis and, in fact, in 5-10% of  the normal population10
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Although immunohistological staining for the composition of these infiltrates (e.g.
determining the percentage of IgA or IgM producing plasma cells) appears to offer
better  disease specificity than assessing the LFS, this  procedure has  not  been
widely applied yet11-13. Thus, whilst the LFS provided an objective tool to distinguish
different pathophysiological conditions all leading to the sicca syndrome, it’s role in
SS  definition  was  much  debated  because  of  the  relative  lack  of  fine  disease
specificity.
Similar controverses occurred following the detection of anti-SS-A and anti-SS-B
autoantibodies in Sjögren’s syndrome in 196014. Serological assessment provided
important  objective  markers  of  the   systemic  component  of  the  disease.  The
observed distinct serological profiles enabled subgroup definition and, similar to the
LFS findings, provided indications for the presence of distinct pathophysiological
mechanisms that lead to the sicca syndrome. However the disease sensitivity and
specificity of the classic anti-SS-A and anti-SS-B antibodies, as well as those of
suggested  alternative antibodies,  such as  e.g.  anti-muscarinic  receptor  or  anti-
fodrin  antibodies15-18,  has  been  limited.  Nevertheless,  it  was  obvious  that  the
systemic  disease  component  differed amongst  the patients  diagnosed  with  SS
using the clinical Bloch definition. Since Henrik Sjögren did not speculate on the
nature of a specific underlying systemic disease and the Bloch definition did not
conflict with findings of distinct underlying systemic diseases, why should the term
Sjögren’s syndrome be preserved for a subgroup of patients? On the other hand, to
get  on  with  research,  having  recognised  distinct  pathophysiological  conditions,
there was a need for consensus on how to classify SS. As a result, in the early 80s
several classification criteria sets for SS were introduced. These sets included both
clinical signs and symptoms of dry eyes and mouth and pathophysiological signs
such  as  salivary  gland  histology  and  serological  evidence  for  an  underlying
systemic disease. Note that these classification criteria are quite compatible with
the  Bloch  concept  and  not  based  on  the  concept  of  SS  as  a  specific
pathophysiological  disease  entity  on  its  own.  Inevitably,  the  SS  population
continues  to  be  heterogeneous,  however  due  to  serological  and  histological
specifications of the systemic component to a lesser extent than before.
The introduction, modifications and merging of SS classification criteria
In  1986  a  number  of  classification  criteria  for  SS  was  proposed  at  the  first
International  Sjögren’s  Syndrome  Symposium that,  given the history  mentioned
above,  was  mainly  focused  on  diagnostic  issues.  Regarding  the  use  of
classification  criteria  no  consensus  was  reached,  and  as  a  result  all  of  the
presented classification criteria were used in the years following this symposium.
This meant that over the years at least five main classification criteria sets were
used in international research: two US sets (Fox’ San Diego and Daniels-Talal’s
San Francisco criteria)19,20, two European sets (Copenhagen and Greek criteria)21,22
and a Japanese set23. Fortunately continuing discussions and accumulating study
data have led to a more uniform diagnostic approach nowadays. The two European
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classification criteria sets soon merged to one so called European Study Group
classification criteria set24. A decade later, at the VIIIth international Symposium on
Sjögren’s  syndrome,  a  combined  US/European  classification  criteria  set  was
introduced25. Unfortunately the Japanese classification criteria have not yet been
included in this new international classification criteria set. In order to come to a
single, worldwide applied, classification criteria set for Sjögren’s syndrome, a final
merging of classification criteria sets is scheduled for the next symposium. In the
current US/European classification criteria presence of either anti-SS-A/anti-SS-B
antibodies  or  a  focus  score  >1  is  obligatory  for  the  classification  Sjögren’s
syndrome.  Thus,  whilst  the usefulness of  both of  these  parameters  was much
debated in 1986, they have nowadays evolved to obligatory items.
Primary and secondary SS: a confusing terminology
In  the  absence  of  serological  or  histological  evidence  for  SS,  some  patients
previously diagnosed as having SS were now considered sicca syndrome patients.
Considering Bloch’s clinical definition of SS, a patient with RA, xerostomia and KCS
could nevertheless still have SS. By introducing the terms primary and secondary
SS this problem was bypassed. However, the agreed upon classification criteria for
secondary SS were less stringent than those for primary SS and did not require
presence  of  either  anti-SS-A  or  anti-SS-B  or  positive  focus  score26.  As  a
consequence, the term secondary SS still covered a heterogeneous population of
patients  with  either  an  overlap  syndrome  of  the  now  as  primary  SS  defined
condition and an other connective tissue disease or sicca syndrome secondary to
e.g.  RA.  This  is  reflected  by  both  pathophysiological  and  clinical  differences.
Primary  SS  is  often  associated  with  the  HLA-DR3  phenotype.  In  contrast,
secondary SS patients with RA are often linked to HLA-DR427-29. Whilst presence of
either anti-SS-A or anti-SS-B antibody is observed in approximately 80% of primary
SS patients, secondary SS patients are frequently ANA positive, but not anti-SS-A
or anti-SS-B positive30. In addition, recently an association between anti-SS-A/SS-B
antibody production and HLA-DR3 was reconfirmed31,32. Furthermore, as mentioned
previously, a positive salivary gland biopsy (focus score >1) is less often observed
in  secondary  SS  as  compared  to  primary  SS.  Moreover,  determining  the
percentage of IgA containing cells in salivary gland infiltrates has been shown to
enable discrimination between rheumatoid  arthritis patients with  sicca syndrome
and true Sjögren’s syndrome patients11.  In the course of the disease primary SS
patients may typically develop central or peripheral nervous system involvement,
hypergammaglobulinemia, purpura, or a malignant lymphoma. In contrast  these
signs are often absent in secondary SS patients whose  sicca symptoms may be
relieved  by  treatment  of  the  underlying  connective  tissue  disease  (e.g.  RA)33.
However,  for  primary  Sjögren’s syndrome there is  no causal  treatment  strategy
available yet. Thus, using the term “overlap syndrome” in case a primary SS patient
also  has  an  other  connective tissue  disease  appears  preferable,  since  from a
pathophysiological point of view Sjögren’s syndrome is not causally related to any
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other connective tissue disease and is therefore not “secondary”. The terms “SS”,
“SS overlap syndrome”  (e.g.  SS/SLE)  and “non-SS sicca  syndrome”  provide  a
more  unambiguous  nomenclature  and  shall  therefore  be  used  throughout  this
thesis.
Early diagnosis as possible future development:
implications for the classification criteria ?
More than a century after the first pathological descriptions by Mickulicz a trend from a
long-lasting emphasis on clinical signs back towards pathophysiological signs can be
noted in the evolving concept of Sjögren’s syndrome. Either serum presence of anti-
SS-A and/or  anti-SS-B antibodies.  or  positive sublabial  or  parotid  salivary  gland
biopsy  is  mandatory  in  the current  classification criteria  and outlines a particular
patient population. This trend may eventually lead to diagnosing Sjögren’s syndrome
at an earlier stage, possibly enabling reversibility of glandular pathology. Presence of
anti-SS-A or anti-SS-B antibodies has also been observed in saliva and tears of SS
patients34-37. Apart from antibody profiles, characteristic early changes in composition
of saliva or tears are also subject of continuing research activities38. In animal models
early histopathological changes are increasingly documented39,40.  When knowledge
about the natural (slowly progressive) course of the disease accumulates and more
tools  for  early  diagnosis  become  available,  the  classical  sicca  symptoms  may
eventually prove to be rather non specific end-stage disease manifestations. Following
new  insights  the  history-based  model  of  Sjögren’s  syndrome  needs  to  be
reconsidered. Implementation of these developments in daily clinical practice will be
challenging.  The  end-stage  disease  sicca  symptoms  have  been  the “trigger”  for
doctors  to  check  whether  the  patient  has  Sjögren’s  syndrome.  So  far  however,
following a diagnosis no lasting curative treatment can be offered to the patient. In
order  to  diagnose  the  syndrome before  irreversible  glandular  damage  occurs,  a
screening test for Sjögren’s syndrome will  have to be considered in a “pre-sicca”
stadium in  which the patient  may only  present  with  non-specific  symptoms.  This
demands a quick, cheap, preferably non-invasive specific and sensitive screening test.
For the moment, the need for early diagnosis before irreversible damage has taken
place, may not be widely felt before disease-modifying treatments are available.
1.2 - Pathogenesis and pathophysiology of Sjögren’s syndrome
Sjögren’s  syndrome  (SS)  is  generally  considered  an  autoimmune  exocrinopathy.
Despite extensive research the exact pathogenesis of this exocrinopathy remains to
be elucidated.  Various patho-physiological disease models for Sjögren’s syndrome
have been suggested and explored. Apart from an underlying genetic predisposition,
endocrine, neurological,  and environmental  factors, as well  as infectious agents
have been put forward as potentially triggering and maintaining primary Sjögren
syndrome.
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Immunogenetic factors in the pathogenesis of Sjögren’s syndrome
A scala of  genes encoding for different  components of the immune system can
potentially account for the genetic predisposition that appears to be present in SS27.
These  include  histocompatibility  genes,  T-Cell  receptor  (TCR)  genes,
immunoglobulin  genes,  antigen-processing  and  peptide  transport  genes  and
complement genes41. Histocompatibility genes are involved in the formation of the T
cell repertoire from the thymus, whilst TCR genes have a role in determining the
number  and  specificities  of  autoreactive  T  cells.  Immunoglobulin  genes  are
responsible for regulation of specificities and idiotypes of natural autoantibodies.
Inefficiently coding antigen-processing and peptide transport genes can impair the
development  of  anergy  whilst  defects  in  complement  genes  may  lead  to
complement deficiency. In other words, polymorphisms in any of these genes may
code for gene products that dysregulate the normal immune function, and thereby
predispose for autoimmune attack. 
Although meanwhile  additional  genes and their  encoded molecules  have  been
explored (e.g.  genes encoding for apoptosis,  or  cytokines)  none have been as
much explored in autoimmunity research as the histocompatibility or HLA genes. A
variety of HLA-DR and later HLA-DQ alleles have been associated with most of the
autoimmune diseases,  including SS. HLA-DR3 and HLA-Dr2 associations  have
been found in western European SS patients and patients with an overlap SS/SLE
or  SS/systemic  sclerosis42.  Interestingly  patients  with  RA  and  secondary  sicca
syndrome have been associated with HLA-DR4 but not HLA-DR3 or HLA-DR243. It
has been noted however that HLA-DR and HLA-DQ associations differ in distinct
ethnic groups. In Greek patients and Israeli Jews e.g. SS is rather associated with
the DR5 allele. Japanese SS patients show other associations44,45. This raises the
question whether SS patients are a genetically heterogeneous group or whether
SS patients differ as a result from various diagnostic criteria sets applied in these
countries.  HLA-DR  and  especially  DQ  alleles  also  seem  to  be  involved  in
autoantibody formation (e.g.,  against  SS antigen-A/Ro and SS antigen-B/La)31,32.
Synthesis of autoantibodies against B-cell epitope analog of SSB/La in Caucasian
patients with primary SS seemed to be dependent on the presence of a permissive
HLA–DQ  heterodimer,  most  prominently  represented  by  HLA–
DQA1*0501/DQB1*0201.  As  a  result  of  this  finding,  a  model  of  HLA-restricted
presentation of SSB/La peptide determinants has been suggested46.
Endocrinological factors in the pathogenesis of Sjögren’s syndrome 
Since Sjögren’s syndrome is a disorder predominantly affecting women a role for sex
steroids  in  the  pathogenesis  has  been  assumed.  The  fact  that  a  number  of
immunoregulatory  features  of  estrogens have  been  described provides  additional
support for this hypothesis. However, previous studies did not elucidate any endocrine
mechanisms directly involved in the pathogenesis of SS or SS/SLE overlap syndrome.
A large proportion of androgens and estrogens in men and women are synthesized
locally  in  peripheral  target  tissues  from  the  inactive  adrenal  precursors
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dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEA-S). In postmenopausal
women, 100% of active sex steroids are synthesized in peripheral target tissues
from inactive steroid precursors. However, in a pilot clinical trial DHEA supplement
treatment   showed  no  evidence of  efficacy  in  primary  SS patients47.  Estrogen
activity has been linked to cutaneous expression of the classic SS antibodies anti-
SS-A and anti-SS-B. Estradiol has been reported to enhance binding to cultured
human keratinocytes of antibodies specific for SS-A and SS-B48-50. It must be noted
that all  studies were performed  in vitro in an experimental setting using cultured
cells. 
Meanwhile, several authors have reported on different localizations and functioning of
two distinct estrogen receptor (ER) types, named ER- and ER-ß, in human tissues.
These studies indicate that ERß is the predominant ER in the skin, salivary glands
and oral epithelium51-53.  This is of  particular interest  if  confirmed in  SS patients
specifically  since  SS  typically  becomes  manifest  in  salivary  glands  and  oral
epithelium. A possible role for ER-ß in triggering or maintaining SS could then be
hypothesized.
Instead  of  focussing  on  estrogen  activity,  androgen-deficiency  might  offer  an
alternative explanation for the sex differences in SS prevalence, as suggested in
recent  studies54,55.  Interesting observations  come from case  studies  of  patients
suffering from Klinefelter’s syndrome (KS). Three patients with KS and SS showed
a clinical remission of SS and a decrease in ANA and RF titers as well as ESR
following treatment with the androgen T undecanoate56. In KS patients testosteron
replacement treatment has also been found to decrease serum levels of IgA, IgG,
IgM, IL-2 and IL-457. This suggests that the lack of testosterone in patients with KS
enhances cellular and humoral immunity and that androgen replacement therapy
may  suppress  this.  Next  to  these  observations  pregnancy,  the  use  of  oral
contraceptives, and postmenopausal hormone replacement therapy all  affect the
course of autoimmune diseases differently. Therefore the role of sex steroids in SS
remains  an  interesting  though  complex  matter  that  needs  further  research,
especially following the recent discovery of a second estrogen receptor ERß and
the recognition of tissue specific intracellular steroidogenic enzyme activity.
Neurological factors in the pathogenesis of Sjögren’s syndrome 
Sicca symptoms in SS have commonly been attributed to lymphocytic infiltration
and destruction of the lacrimal and salivary glands58. However, the severity of sicca
symptoms does not always correlate with the degree of glandular destruction seen
in  labial  biopsy  tissue59.  The  residual  glandular  elements  in  the  salivary  gland
appear  dysfunctional  even  though  they  apparently  maintain  their  neural
innervation60 and  despite  upregulation  of  their  muscarinic  receptors61.  It  is
hypothesized that this suboptimal function of the residual acinar and ductal cells,
leading  to  sicca  symptoms,  may  result  from  local  action  of  e.g.  cytokines,
autoantibodies  and  metalloproteinases  or  from  parasympathetic  neural
dysfunction62. Features suggestive of dysfunction of the autonomic nervous system,
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including  Adie’s  tonic  pupil63,  fluctuating  blood  pressure  and  orthostatic
hypotension64, anhidrosis65, and constipation66, have been reported to occur in SS.
A prospective study of 32 SS patients showed presence of autonomic neuropathy
in the majority of patients67. Bladder symptoms have also been reported, including
frequency  of  micturition,  nocturia,  urgency,  and  incomplete  bladder  emptying,
frequently in association with interstitial cystitis68. Muscarinic receptors of the M3
subtype  mediate  the  stimulatory  effects  of  acetylcholine  on  the  lacrimal  and
salivary glands, as well  as the contractile effects of acetylcholine on the bladder
and  intestinal  smooth  muscle  and  on  nitric  oxide  production  in  blood  vessels.
Salivary IgA autoantibodies against  M3 muscarinic acetylcholine receptors have
been proposed as a marker to differentiate Sjögren syndrome from non-Sjögren
syndrome  xerostomia69,  whereas  serum  IgG  autoantibodies  against  the  M3
receptor  have recently  been shown to  reversibly  inhibit  the mechanism of  fluid
secretion by human submandibular salivary acinar cells70.  Therefore, muscarinic
receptors  have  been identified as  a  rational  target  of  drug therapy  by  specific
agonists.
Infectious factors in the pathogenesis of Sjögren’s syndrome
Several infectious agents have been suggested to trigger SS. Bacterial and mycotic
agents present  in the oral  cavity or in salivary cultures have been identified as
related to  SS71-73.  However whether  these agents were the cause or  rather the
result of SS can be questioned. Viral agents, in contrast to other infectious agents
have drawn much more attention in SS research. Hepatitis C virus (HCV), herpes
viruses  (e.g.  Epsten-Barr  virus,  cytomegalovirus,  human  herpes  virus-6),  and
retroviruses (AIDS HTLV-1)  have all  been linked to  SS74,75.  Herpes viruses and
retroviruses  have  sialotropic  and  lymphotropic  properties.  Their  localization  to
salivary glands could lead to primary pathology and lymphotropism could lead to
dysregulation  of  the  immune  system.  However,  not  any  of  the  proposed  viral
triggers  was  detected  constitutively  in  patients  with  Sjögren  syndrome  or  was
specific for Sjögren syndrome.
Pathophysiological aspects of Sjögren’s syndrome
B cell hyperreactivity and lymphoplamacytic infiltrations of exocrine glands are the
major autoimmune characteristics of SS76. Glandular destruction in SS has been
shown to be mediated by primed CD4+ T helper and inducer lymphocytes77 which
may also explain high B cell activity. However, salivary and lacrimal glands from SS
patients  have  an  impaired  secretory  function,  even  during  the  initial  phase  of
inflammation  and  onset  of  lymphocytic  destruction.  Next  to  structural  loss  of
glandular  elements  and  parasympathetic  neural  dysfunction,  the  release  of
proinflammatory cytokines (such as TNF-alpha) by both lymphocytes and glandular
cells, induction of matrix metalloproteinases78, as well as an impaired release of
and response to neurotransmitters may be involved in the loss of secretory function
of the residual glandular cells in SS79.
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Systemic  autoimmune  diseases  such  as  Sjögren  syndrome,  systemic  lupus
erythematosus, and rheumatoid arthritis appear to have characteristic patterns of
B-lymphocyte  distribution80.  B  cell  activity  in  the  salivary  glands  enables
quantitative immunohistological evaluation of submandibular salivary gland biopsy
specimens. Measurement of the number and distribution of immunoglobulin isotype
producing plasmacells has been shown to be superior to lymfocytic focus score
assessment in the diagnosis of SS11-13. In SS patients a significant decrease in the
frequency of  peripheral memory CD27+  B cells81 has  been found. Whether the
reduction of circulating CD27+ memory B cells in SS results from disturbed B-cell
differentiation82,  preferential  trafficking  or  homing of  memory  B cells  into  target
tissues83,  or  alternative  B-cell  activation pathways via  toll-like  receptors84 is  not
known yet. Recently promising results of anti-B-cell treatment strategies in SS have
been reported85,86.
Autoantibodies are frequently found in SS and directed to a wide range of antigens.
The significance of individual autoantibodies and their potential role in triggering or
maintaining SS has been much studied as well as debated. So far, although also
found in  SLE, antibodies  directed to  the SS-A (Ro) and SS-B (La) antigen are
considered as the most disease sensitive (60–75% and 30–50%, respectively) and
specific serological  markers of  SS. As a consequence anti-SS-A and anti-SS-B
play an important role in current  classification criteria for SS. Although antibodies
targeting  a  variety  of  candidate  autoantigens  (more  recently  alpha-fodrin  and
muscarinic  M3 receptor)  have  been  suggested  as  alternative  disease  markers,
none  of  them  has  proven  to  be  superior  to  anti-SS-A  and  anti-SS-B15-18.
Nevertheless, in approximately 20% of SS patients no anti-SS-A and anti-SS-B can
be detected at the time of diagnosis. In conclusion, SS-associated autoantibodies
although  significantly  contributing,  do  not  provide  the  golden  standard  for  the
objective diagnosis of SS.
Natural course of Sjögren’s syndrome
Unlike other rheumatic diseases, such as rheumatoid arthritis and SLE, the clinical
course of  SS tends to  be stable  and is  characterised by unchanged or slowly
deteriorating exocrine  gland  function  over  time.   Exacerbations  or  “flares”  are
rather infrequently seen or reported in the course of SS. In a recent study only 3-
7% of a cohort of SS patients (as compared to 62% in SLE) reported having had
one or more flares per year87. Fatigue and arthralgia were the main constituents of
reported  flares  in  this  population.  Few  longitudinal  studies  in  SS  have  been
published. Kruize88 performed a 10-12 year follow-up study and concluded that SS
is characterized by a stable and rather mild course of glandular and extraglandular
manifestations.  During  follow-up  3  of  30  SS  patients  developed  and  died  of
malignant  lymphoma.  Similar  reports  come  from  a  study  in  the  North-East  of
England  Davidson89.  Stable clinical  features  were  observed in  100  SS patients
following 10 years of follow-up. Three of these patients, all anti-SS-A and anti-SS-B
positive,  developed malignant  lymphoma. For  anti-SS-A and  anti-SS-B  positive
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patients in this follow-up cohort the relative risk of developing malignant lymphoma
was 49. Gannot90 also noted a stable clinical course in a 5-10 year follow-up study
of 80 SS patients. Despite the observed clinically mild course, these longitudinal
studies all confirmed that SS patients are at significantly increased risk to develop
malignant lymphoma (see below).
 
Lymphomagenesis
Sjögren  syndrome patients  are at  increased risk  to  develop  B-cell  lymphomas,
which occur 16 to 44 times more frequently in patients with  SS than in normal
healthy  subjects.  Most  commonly  the  lymphoma  is  of  the  mucosa-associated
lymphoid tissue (MALT) type91-93. These MALT lymphomas are thought to originate
in the organs targeted by Sjögren syndrome and spread to other mucosal sites over
time93-95. Based on recent long-term outcome studies in primary Sjögren syndrome
patients, the presence of palpable purpura, low C4 levels and a low CD4+/CD8+ T
lymphocyte ratio have been proposed as predictive factors distinguishing patients
at high risk for developing lymphoma from patients with an uncomplicated disease
course92,96.
1.3 - Can disease activity be assessed in Sjögren’s syndrome ?
Reversibility in Sjögren’s syndrome
Reversibility is an essential component of the currently proposed disease activity
model97. However, in SS objectively documented clinical or histological reversibility
is restricted to  a  few case reports.  Because therapeutic interventions  are often
based  on  an  anti-inflammatory  approach  this  might  reflect  lack  of  an  active
inflammatory process. Lack of inflammation might result from SS diagnosis in a
relatively late stage of the disease or from an active underlying disease process
that is not accompanied by inflammation. The latter hypothesis might be supported
by  the  reported  improvement  of  Schirmer  tests  following  pilocarpin  treatment.
However,  the  reproducibility  of  Schirmer-tests  and  their  correlation  to  clinical
symptoms has been questioned98. 
Systemic symptoms such as fatigue and arthralgia play a prominent role  in SS
patients and are a target of therapy. However, reversibility of these features can not
be  objectively  evaluated  and  has  to  be  assessed  by  e.g.  questionnaires  and
patients  reports.  In  concordance  with  the  described  non-fluctuating  slowly
progressive course of SS, significant  changes in laboratory parameters such as
antibody levels, ESR, hypergammaglobulinemia, are not frequently observed. 
To  date,  case  reports  describing  reversibility  of  histological  changes  in  biopsy
specimens  following  cortcosteroid  or  anti-B-cell  treatment  provide  the  sole
objectively  documented  examples  of  reversibility  in  SS.  In  two  case  reports
normalisation  of  histopathological  changes  following  high  dose  corticosteroid
treatment is  observed99,100. A similar  normalisation  was noticed in  a  female  SS
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patient suffering from interstitial nephritis. After high dose corticosteroid treatment
renal  biopsy  showed  a  markedly  improved  picture.  Changes  in  salivary  gland
immunohistology and function following anti-B cell monotherapy have recently been
shown in a patient with SS and MALT lymphoma101. Since reports on reversibility in
SS are restricted to individual  case reports it  remains to  be elucidated to what
extent clinical and histological symptoms and signs are reversible in SS.
Disease activity
Although no effective systemic treatment is available to date it must be noted that in
clinical trials  treatment efficacy is mainly clinically evaluated using a wide range of
non-uniform objective and subjective parameters. A need for an uniform objective
disease  activity  parameter  is  widely  felt.  However,  since  both  the  definition  of
Sjögren’s  syndrome  and  knowledge  of  its  pathophysiology  are  evolving  as
described before, establishing and validating a widely agreed upon disease activity
parameter  is  easier  said  than  done.  In  March 2000 collaborative  research  into
outcome measures in  Sjögren's  syndrome was initialized102.  Several  workshops
and consensus meetings have led to proposals of two disease monitoring tools for
Sjögren's syndrome, the BILAG-SS and the ECLAM-SS (not published yet). The
BILAG-SS has already been applied in  an analysis  of  anti-SS-A and anti-SS-B
antibody  levels and their  relation to disease activity103.  Both the BILAG-SS and
ECLAM-SS  are  modified  versions  of  disease  activity  tools  for  monitoring  SLE
(ECLAM  stands  for  European  Consensus  Lupus  Activity  Measurement  whilst
BILAG stands for British Isles Lupus Assessment Group). Recently a prospective
study was presented showing that the total scores of both BILAG-SS and ECLAM-
SS  correlate  well  with  each  other104.  Since  a  disease  activity  monitoring  tool
specifically  designed  for  SS is  still  lacking this  appears  a  promising  approach.
Disease monitoring tools that  have previously been developed for RA and SLE
have  led  to  significant  advances  in  research  and  follow-up  studies  of  these
conditions.  However,  in  validating disease activity tools for SS several  disease-
specific difficulties will be encountered and will have to be solved. As mentioned
previously, in contrast to e.g. In RA or SLE, exacerbations or “flares” are rather
infrequently seen or reported in the course of SS and not associated with elevated
ESR or CRP levels87. Longitudinal studies confirm the stable clinical course of SS.
The apparent non-fluctuating slowly progressive course and the lack of measurable
exacerbations  makes  defining  and  monitoring  disease  activity  in  SS  a  difficult
issue.  In  developing a disease activity tool for SS these stable disease course
features were recognised. Therefore the idea of disease activity solely based upon
inflammation was left  behind.  This is in  concordance with the fact  that  disease
activity  as  perceived  by  the  patient  is  often  not  accompanied  by  increased
inflammatory parameters. Disease activity has now been defined as those disease
characteristics  that  are  potentially  reversible,  regardless  of  the  pathogenic
mechanism, as opposed to damage which by definition is irreversible105. Apart from
the fact that little is known about reversibility in Sjögren’s syndrome, this approach
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has led to  a  prominent  role  for  arthralgia  and fatigue as  (indirect)  markers  of
systemic disease activity.  However,  these symptoms are inevitably subjective of
nature  and  unlike  e.g.  arthritis  do  not  lead  to  end-organ  damage.  Defining  a
disease severity (or damage) index to start with may be more suitable given these
considerations. However, so far only a single study of end-organ damage has been
performed in SS patients106. A proper definition of end-organ damage in SS may be
helpful in the further development of a disease activity tool.
1.4 - Treatment: localized and systemic approaches
Thus far,  no effective systemic treatment is available  for SS. Disease-modifying
anti-rheumatic drugs (DMARDs) which are successfully applied in the treatment of
several  other  rheumatic  diseases  did  not  turn  out  to  be  a  successful  overall
approach in  SS107-109.  In some cases glucocorticoids  are reported to  offer  some
subjective improvement such as a decrease of fatigue complaints, but the efficacy
of corticosteroid treatment in SS has not been objectively documented in placebo-
controlled  studies110.  Patients  with  Sjögren’s  syndrome  also  encounter  greater
problems with  corticosteroids,  including acceleration of  periodontal  disease and
oral candidosis. The use of corticosteroids in SS is therefore restricted to treat life-
threatening  complications,  such  as  severe  vasculitis  or  interstitial  nephritis.
Hydroxychloroquine  can  be  useful  in  decreasing  arthralgia,  myalgia,  and
lymphadenopathy111.  Kruize  and  colleagues noticed  that  following  hydroxy-
chloroquine treatment ESR decreased, but tear flow volumes did not increase112.
In the absence of effective systemic treatment SS is mainly treated symptomatically
and locally  using  eye  droplets  and artificial  saliva.  Furthermore  M3 muscarinic
receptor  agonists  such as pilocarpine and cevilemine may enhance autologous
production of both saliva and tears in a subgroup of SS patients113,114.  Recently
new biological agents that are already applied in the management of various other
autoimmune diseases such as rheumatoid arthritis and Crohn’s disease, have been
evaluated in SS. Examples include tumour necrosis factor (TNF)-alpha  inhibitors115-
117 and anti-B cell  agents. Promising results have been reported concerning the
efficacy of anti-CD20 treatment in SS85,86. However the ideal treatment modality for
SS has yet to be developed. 
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1.5 - Aims and outline of the thesis
In the recently presented combined US/European classification criteria for SS more
weight  is  put  on presence of  disease characteristic  serological  and histological
signs.  These include the serum presence of  anti-SS-A-  and anti-SS-B-antibody
(anti-SS-A, anti-SS-B), as well  as the extent  of  lymphocyte infiltrates in salivary
gland biopsy specimens, expressed in a so-called lymphocytic focus-score (LFS).
Since in approximately 20% of SS patients no serum presence of anti-SS-A and
anti-SS-B can be detected at the time of diagnosis, the additional value of repeated
serological examination in SS patients was evaluated after disease had progressed
for at least 5 years. Because exocrine gland products can also show (enriched)
anti-SS-A and anti-SS-B presence, the tear fluid of seronegative SS patients was
analysed for presence of anti-SS-A or anti-SS-B. The potential additional diagnostic
value of anti-alpha-fodrin antibodies as alternative serological marker for SS was
evaluated.
In salivary gland biopsy specimens the LFS was compared to the percentage IgA
containing plasmacells, after both parameters had been assessed for 10 years in
our  hospital.  Reversibility  of  these  (immuno)histological  characteristics  following
anti-inflammatory  treatment  was evaluated.  For  this  purpose,  repeated salivary
gland biopsy was performed both before and after anti-TNF-alpha treatment in an
open label pilot study in SS patients. Whether a skin biopsy could serve as an
alternative  for  salivary  gland  biopsy  by  revealing  similar  exocrinopathy
characteristics  was  also  explored.  Thus,  in  concordance  with  the  increased
emphasis on serological and histological signs in recent classification criteria, this
thesis is aimed at optimised use of objective signs in the diagnosis of  Sjögren’s
syndrome.
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ABSTRACT
Objective: 
Approximately 20 percent of  Sjögren’s syndrome (SS) patients lack serum presence of anti-
SS-A and anti-SS-B antibodies (anti-SS-A, anti-SS-B), which is an emphasized item in the
US/European Consensus Group (EUCG) classification criteria for SS. However, anti-SS-A and
anti-SS-B can also be found in saliva and tear fluid, as shown previously in SS patients with
a positive serological profile. The aims of this study were to evaluate presence of anti-SS-A
and anti-SS-B in the tear fluid of SS patients without serum presence of these antibodies,
and to re-assess their serological profile after at least 5 years of disease duration.
Methods: 
Tear fluid presence of anti-SS-A and anti-SS-B was assessed by ELISA in 13 seronegative
SS  patients.  Tear  samples  of  three  seropositive  SS patients served  as  control.  All  SS
patients fulfilled the EUCG classification criteria. New blood samples were taken from 17
previously  seronegative  SS  patients,  all  with  a  disease  duration  of  at  least  five  years.
Presence of anti-SS-A or anti-SS-B in these serum samples was measured using counter-
immuno-electrophoresis and ELISA.
Results: 
Tear fluid presence of anti-SS-A was found in 2 of 13 seronegative SS patients. Both anti-
SS-A and anti-SS-B were found in the tear fluid of all 3 seropositive SS patients. No sero-
conversion was observed in seronegative SS patients.
Conclusion: 
In seronegative SS patients tear fluid analysis, in contrast to repeated serological analysis,
might reveal anti-SS-A presence, thereby facilitating the diagnosis of Sjögren’s syndrome.
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INTRODUCTION
In  the current  US/European Consensus Group (EUCG) classification criteria for
Sjögren’s syndrome (SS) objective items, such as serum presence of  anti-SS-A
and anti-SS-B antibodies (anti-SS-A, anti-SS-B), are emphasized1.
In the sera of approximately 20% of SS patients no anti-SS-A or anti-SS-B can be
detected at the time of diagnosis. However, in these ‘seronegative’ patients anti-
SS-A or anti-SS-B may nevertheless be present in other body compartments, e.g.
within the exocrine glands. Various indications for local autoantibody synthesis in
salivary glands of SS patients have been reported previously2-4. Therefore it has
been recognized that in SS patients anti-SS-A or anti-SS-B might also be detected
in the products of the major target organs, i.e. in saliva or tears. However, to our
knowledge anti-SS-A or anti-SS-B presence in the tear fluid of SS patients has only
been reported once5.  Interestingly,  anti-SS-A and anti-SS-B presence  was also
demonstrated in  the tear fluid of  1  of  12 and  4 of  14 seronegative SS patients
respectively.  In contrast to this single report on tear fluid, anti-SS-A or anti-SS-B
presence in  the saliva of SS patients has been observed in several studies2,6,7.
From the observed relatively increased salivary antibody levels as compared to
serum levels, it has been suggested that these antibodies are synthesized within
the salivary glands and that they can be detected in saliva before they become
present in the peripheral circulation7. Likewise we hypothesised that anti-SS-A or
anti-SS-B synthesis within the lacrimal glands of SS patients might result in tear
fluid presence of anti-SS-A or anti-SS-B, even in the absence of serum presence of
these antibodies. 
Furthermore  we  hypothesized  that  following  prolonged  inflammation  with
accompanying  local  antibody  formation  in  exocrine  glands,  the  antibody  may
become present  in  the  peripheral  circulation  as  disease  progresses.  Previous
follow-up studies have not been aimed at anti-SS-A and anti-SS-B seronegative SS
patients  specifically8-11.  In  general  a  stable serological profile  is  observed in  the
course of SS. However, seroconversion from a negative to positive anti-SS-A or
anti-SS-B serological profile was noted in one of these studies in 14% and 16% of
SS  patients  respectively11.  If  confirmed,  this  would  implicate  that  in  some
seronegative patients initially not fulfilling the classification criteria for SS, repeated
measurement of anti-SS-A and anti-SS-B could result in diagnosing SS on second
occassion. 
The aims of this study were to assess whether anti-SS-A and anti-SS-B could be
detected in tear fluid samples of our seronegative SS patient population, and to
examine whether seroconversion to a positive profile occured after disease had
progressed for at least five years since diagnosis.
METHODS
All patients who were asked to participate gave their informed consent before blood
or tear fluid withdrawal was done.
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Patients, tear fluids and sera
Tear  fluid was collected from 13 anti-SS-A and anti-SS-B seronegative patients
fulfilling the EUCG criteria for SS, and  3 anti-SS-A and anti-SS-B seronegative
focal  sialadenitis  patients.  Tear  fluid  samples  of  3  anti-SS-A  and  anti-SS-B
seropositive SS patients served as control. Tear fluid was obtained using Schirmer-
test paper strips placed in the lower conjunctival sac for 10 minutes. The paper was
then stored in 0.5ml phosphate buffered saline (PBS) and immediately stored at –
70º Celsius.
New serum samples taken from 26 patients with sicca symptoms, that were anti-
SS-A and anti-SS-B seronegative in the past, were tested for presence of these
antibodies. Of these 26 patients 17 fulfilled the EUCG classification criteria for SS.
The  remaining 9  patients  were  considered  as  focal  sialadenitis  patients (focus
score >1, but not fulfilling the UECG criteria). In addition, new serum samples of 16
previously anti-SS-A and anti-SS-B seropositive SS patients, all fulfilling the UECG
criteria, were tested. The time interval between initial and second blood sampling
ranged between 5 and 12 years.
Measurement of anti-SS-A / anti-SS-B in serum by counter-immunoelectroforesis (CIE)
Sera obtained after new blood withdrawals were analysed for presence of anti-SS-A and
anti-SS-B by CIE, which was also used in the past for analysis of sera obtained at initial
diagnosis.  For CIE the procedure described by Bunn and Kveder12 was performed, using
bovine spleen extract (BS) for detection of anti-SS-A, and rabbit thymus extract (RT)  for
detection of anti-SS-B. Plates coated with agarose type L (Behring®) in ENA buffer were
used  for  electrophoresis  with  the  antigen  (BS/RT)  during  75  minutes,  after  an  initial
electrophoresis without antigen during 15 minutes. Plates remained in ENA buffer overnight,
and were then transferred to phosphate buffered saline (PBS) for 24 hours. Thereafter the
plates were washed once with distilled water (dH2O) and then stained with Coomassie blue
solution during 4 minutes. After staining the plates were washed again with dH2O and drying
of the the gel was done using a hair dryer. For confirmation all sera were also tested using
the ELISA that was used for tear fluid measurement.
Measurement of anti-SS-A and anti-SS-B in tear fluid by ELISA
Presence of  IgG anti-SS-A and IgG anti-SS-B in tear  fluid samples was determined by
ELISA using Quanta LiteTM SS-A 708570 and Quanta LiteTM SS-B 708575 assays (Inova
Diagnostica,  Inc.  San  Diego)  respectively,  both  with  anti-IgG  conjugate  antibodies.  The
ELISA was performed as recommended by the supplied manufacturers manual. Dilution of
tear samples was not performed because the tear samples were already diluted in PBS
before storage.
RESULTS
Anti-SS-A or anti-SS-B presence in tear fluid
Very low amounts of  tear fluid (approximately 5  l per sample) were obtained.
Despite this, the ELISA showed anti-SS-A presence in  the tear fluid of  2 of 13
seronegative  SS  patients.  From  these  two  patients  tear  fluid  was  afterwards
collected and tested again and this confirmed the presence of anti-SS-A. No anti-
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SS-B presence was observed. Both anti-SS-A and anti-SS-B were found in the tear
fluid  samples  of  all  three  seropositive  SS  patients.  Tear  fluid  samples  of
seronegative focal sialadenitis patients were negative for both anti-SS-A or anti-SS-
B (Table I).
 
Table I: Tear fluid presence of anti-SS-A and anti-SS-B in patients 
with Sjögren’s syndrome (SS) and Focal Sialadinitis (FS)
serum tear fluid
n anti-SS-A anti-SS-B anti-SS-A anti-SS-B
 SS 3 3 3 3 3
 SS 13 0 0 2 0
 FS 3 0 0 0 0
(Table shows number of positive serum and tear fluid samples)
Anti-SS-A and anti-SS-B serological profile
No anti-SS-A or anti-SS-B presence was found in the 26 sera of patients that were
previously seronegative (Table II). Serum presence of anti-SS-A and anti-SS-B was
confirmed  in  all  16  previously  seropositive  SS  patients.  Taken  together,  no
seroconversion was observed.  
Table II: Serum presence of anti-SS-A and anti-SS-B 
after at least five years since initial diagnostic measurement
diagnostic measurement 2nd measurement after > 5 years
n anti-SS-A anti-SS-B anti-SS-A anti-SS-B
 SS 17 0 0 0 0
 SS 16 16 16 16 16
 FS 9 0 0 0 0
(Table shows number of positive serum samples in CIE as well as ELISA)
DISCUSSION
SS patients lacking serum presence of  anti-SS-A and anti-SS-B are a relatively
understudied population in research on SS. However, since exocrinopathy is the
most striking phenomenon in SS, an alternative for serological analysis in these
patients  might  be  found  in  evaluating  anti-SS-A  or  anti-SS-B presence  in  the
affected glands or their excreta. In this study tear fluid presence of IgG anti-SS-A
was  demonstrated  and  reproduced  in  2  of  13  seronegative  SS  patients.
Furthermore tear  fluid  presence  of  both anti-SS-A and anti-SS-B was found in
seropositive SS patients. Our results support findings of  Toker et  al.5 who, also
using ELISA, demonstrated IgG anti-SS-A and IgG anti-SS-B in tear fluid of SS
patients.  However,  our  study  is  limited  by  the  small  number  of  evaluated
seromegative patients and the small volumes of tear fluid that were obtained. The
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latter did not allow tear fluid evaluation using a confirmation technique for ELSIA,
such as CIE. Nevertheless, a remarkably low amount of tear fluid (approximately 5
l) appeared to be enough to detect anti-SS-A by ELISA.
Obtaining larger tear fluid volumes and assessment of IgA and IgM anti-SS-A and
anti-SS-B in addition to IgG antibody could result in a higher sensitivity.  Further
studies  should elucidate whether  the sensitivity  of  these antibodies is higher  in
exocrine gland products than in sera. Since apparently tear presence of anti-SS-A
or anti-SS-B is  not  necessarily associated with  serological  presence,  combined
measurement of  both body fluids may facilitate clinical  diagnosis of  SS patients
with a negative anti-SS-A and anti-SS-B serological profile. 
In this study no conversion from a negative to positive anti-SS-A and anti-SS-B
serological  profile  was  found  in  17  seronegative  SS  patients.  Although  in  our
hospital the number of anti-SS-A and SS-B seronegative SS patients is low, we
evaluated  twice  as  much  seronegative  SS  patients  as  compared  to  currently
available  previous  reports9,10.  In  the  examined  focal  sialadenitis  patients  serum
samples also remained negative for anti-SS-A and anti-SS-B. Had this not been the
case then these patients would have been diagnosed as having SS according to
the EUCG criteria.
In conclusion, this study confirms that anti-SS-A presence can be found in the tear
fluid of some seronegative SS patients, and that both anti-SS-A and anti-SS-B can
be found in the tear fluid of seropositive SS patients. Furthermore the presence of a
stable  anti-SS-A  and  anti-SS-B  serological  profile  in  the  course  of  SS  was
confirmed. Thus, in contrast to repeated serological analysis (which appears of no
additional diagnostic value), optimized tear fluid analysis might reveal anti-SS-A or
anti-SS-B presence in seronegative SS patients, thereby facilitating the diagnosis
of Sjögren’s syndrome.
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ABSTRACT
The presence of anti-alpha-fodrin autoantibodies has been reported to be a highly specific
and sensitive test for the diagnosis of Sjögren’s syndrome (SS). We looked (in Nijmegen) for
anti-alpha- fodrin, anti-SS-A60, and anti-SS-B autoantibodies in a cohort of 51 patients with
rheumatic  diseases  (21  primary  SS,  6  secondary  SS,  12  rheumatoid  arthritis  (RA),6
systemic lupus erythematosus (SLE), and 6 scleroderma) and in 28 healthy subjects, using
ELISA, immunoblotting, and immunoprecipitation. The same samples were analyzed with an
alternative anti-alpha-fodrin ELISA in Hanover. The Nijmegen ELISA of the sera from primary
SS showed sensitivities of 43% and 48% for IgA- and IgG-type anti-alpha-fodrin antibodies,
respectively. The Hanover ELISA showed sensitivities of 38% and 10% for IgA- and IgG-type
anti-alpha-fodrin  antibodies,  respectively.  The  ELISAs  for  alpha-fodrin  showed  six
(Nijmegen) and four (Hanover) anti-alpha-fodrin-positive RA sera. IgA and IgG anti-fodrin
antibodies were also present in four patients with secondary SS. The sensitivities of Ro60
and La-antibodies in the Nijmegen ELISA were 67% and 62%, respectively. Unlike anti-
alpha-fodrin antibodies, all anti-SS-A60 and anti-SS-B positive sera could be confirmed by
immunoblotting or RNA immunoprecipitation. Thus, anti-SS-A and anti-SS-B autoantibodies
were  more  sensitive  than  anti-alpha-fodrin  autoantibodies  in  ELISA  and  were  more
frequently confirmed by other techniques. anti-SS-B antibodies appear to be more disease-
specific than anti-alpha-fodrin antibodies, which are also found in RA sera. Therefore, the
measurement of anti-alpha-fodrin autoantibodies does not add much to the diagnosis of
Sjögren’s syndrome.
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INTRODUCTION
Sjögren’s  syndrome  (SS)  is  a  chronic  autoimmune  exocrinopathy  of  unknown
origin. Therefore the diagnosis of SS, in the absence of a gold standard, is based
on criteria containing a number of subjective and objective signs and symptoms. In
the past three decades, several sets of criteria have been introduced1–4, in which
there has been a shift from emphasis on subjective symptoms, such as complaints
of dry eyes or dry mouth, towards objective findings. Recently, a widely supported
consensus  was  established  to  merge  the  most  frequently  used  European
(European Study Group (ESG)) and US (San Diego, San Francisco) classification
criteria sets into one US/European set5. The authors of all three major classification
criteria sets previously used took part in this consensus group. In the US/European
classification criteria, more weight is put on the presence of anti-SS-A and anti-SS-
B antibodies  in  the  serum,  and  on  the  lymphocytic  focus  score  (LFS)  of  the
sublabial glands, both being objective signs. The cutoff point of a positive LFS was
 set at >=1.0, which ended a long-lasting debate about whether an LFS of >=1.0
(ESG criteria), >1.0 (San Francisco criteria), or >=2.0 (San Diego criteria) was most
applicable for the diagnosis of SS. This agreement ultimately will produce uniform
intercontinental  disease  prevalence  data.  However,  the  disease  specificity  of
particularly anti-SS-B anti- bodies is limited (besides being found in SS, they are
also found in systemic lupus erythematosus (SLE)), and the sensitivities of anti-SS-
A and anti-SS-B antibodies range only from 60–75% and 30–50%, respectively6–9.
Therefore, the search for more sensitive and specific diagnostic markers needs to
be continued.
Haneji and co-workers10 suggested a 120-kDa cleavage product of alpha-fodrin (a
cytoskeletal  protein)  as a candidate autoantigen in  SS. They reported that  the
presence of anti-alpha-fodrin antibodies was very specific for the diagnosis of SS
and claimed a very high sensitivity (96%). In another report of the same group,
however, these antibodies were also found in some sera of  patients with SLE11.
Their results suggested that anti-alpha-fodrin antibodies might replace anti-SS-A
and anti-SS-B antibodies, as a more objective serological marker to improve the
diagnostic value of classification criteria. This suggestion was supported by Witte
and co-workers,  who  developed  an ELISA or  the detection of  anti-alpha-fodrin
antibodies and showed that IgA antibodies against alpha-fodrin provided an even
higher sensitivity than IgG antibodies12. The objective of this study was to measure
the presence of anti-alpha-fodrin antibodies in the sera of a cohort of patients with
well-defined  SS at  the Department  of  Rheumatology  of  the  University  Medical
Center  St  Radboud,  Nijmegen,  The  Netherlands.  A  second  objective  was  to
evaluate whether positive anti-fodrin ELISA results could be confirmed by at least
one  alternative  biochemical  technique  such  as  immunoblotting  or  protein
immunoprecipitation.  
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MATERIALS AND METHODS
Patients and measurement techniques
The sera of  21 patients (18 women and 3 men, aged 27–76 years,  median 55
years) with well-defined primary SS according to the US/European criteria5 were
tested along with the sera of 6 patients with secondary SS (all women, aged 41–55
years),  28 normal  healthy subjects  (NHS) (19 women and 9 men, aged 24–61
years, median 43 years),  12 patients with rheumatoid arthritis (RA) and without
signs of secondary SS (8 women and 4 men, aged 32–72 years, median 47 years),
6 with SLE (all women, aged 33–56 years), and 6 with systemic sclerosis (SSc) (3
women and 3 men, aged 36–49 years). All the patients tested were white. To fulfill
the US/European classification criteria, all SS patients had to have a biopsy of the
sublabial  salivary  glands  showing  an  LFS  >= 1.0.  Furthermore,
immunohistochemical  examination  had  to  show  a  percentage  IgA-containing
plasma cells of less than 70, a feature that is also strongly associated with SS and
slightly more disease specific than the LFS13,14. The comorbidity of the six patients
with secondary SS is shown in Table 1. Secondary SS was accompanied by SLE in
four patients, by systemic sclerosis in another patient, and by dermatomyositis in
yet another. None of the SS patients was receiving an immunosuppressant. The
presence  of  anti-alpha-fodrin  antibodies  in  the  sera  was  measured  with  three
different biochemical techniques: ELISA, immunoblotting with recombinant fodrin,
and immunoprecipitation of radiolabeled fodrin. Furthermore, a blinded set of our
serum samples was analyzed by Witte and co-workers using the anti-alpha-fodrin
ELISA developed in Hanover, Germany (referred to as Hanover ELISA)12. 
Expression of the 120-kDa alpha-fodrin fragment
For the expression of the antigenic fodrin fragment, we used the alpha-fodrin cDNA in a GST
expression vector  (pGEX-4T2),  which was kindly supplied by Dr  Y  Hayashi  (Tokushima
University School of Dentistry, Tokushima, Japan). The cDNA was expressed in BL21 (DE3)
cells, and the protein was affinity-purified using glutathione Sepharose beads (Amersham
Pharmacia Biotech).
ELISA
The presence of IgA, IgG, and IgM anti-alpha-fodrin antibodies in sera in 100-fold dilution
was assessed by ELISA. Plates were coated with purified alpha-fodrin–GST as antigen, and
bound antibody was detected essentially as described by Schellekens and colleagues15,
using rabbit peroxidaseconjugated anti-human immunoglobulins (anti-IgG, anti- IgA, or anti-
IgM, DAKO, Glostrup, Denmark). Sera were considered positive when the optical density at
450 nm values after correction for background value exceeded the mean +2 SD of that of a
pool of sera from NHS. All ELISAs were performed in duplicate. To checkfor possible false-
positive results because of the presence of the GST moiety in the alpha-fodrin–GST product
that was used as the antigen, the ELISA was also performed in the presence of a 10-fold
excess of purified carrier GST. anti-SS-B (SS-B) and anti-SS-A (SS-A) autoantibodies were
measured by ELISA, using recombinant La and Ro60 proteins. All sera were also analyzed
by immunoblotting and RNA immunoprecipitation to confirm the presence of anti-SS-A and
anti-SS-B antibodies, as previously described16. 
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Immunoblotting
To  confirm  the  ELISA  results,  reactivity  of  sera  againstrecombinant  fodrin–GST  was
evaluated  by westernblotting essentially  as described  elsewhere17.  Thehuman sera were
diluted  5000-fold  with  blocking  buffer.  Asecond  antibody  directed  against  total
humanimmunoglobulin  was  used  (DAKO,  Glostrup,  Denmark).  Ina  similar  type  of
experiment, immunoblots containingextracts from apoptotic Jurkat cells, prepared according
tothe method of Zampieri and colleagues18 and believedto contain the native and possibly
modified apoptotic  alpha-fodrin fragment of 120 kDa described by  Haneji  andcoworkers,
were used. Visualization was performed bychemiluminescence.
Immunoprecipitation of radiolabeled alpha-fodrin
For labeling of cellular proteins, HeLa cells were incubated
in medium without methionine and supplied with 2% dialyzed fetal calf serum (FCS). After 1
hour, 10 Ci 35S-methionine per ml was added and the concentration of dialyzed FCS was
raised to 5%. After an additional 4 hours, 1 volume of complete medium containing 10%
FCS (undialyzed) was added and incubation was continued for 16 hours at 37°C. The cells
were collected by centrifugation, washed, and homogenized in lysis buffer (50mM Tris/HCl,
pH 7.5, 0.5% NP40, 100mM KCl, 1mM
dithioerythritol, 1mM EDTA) containing a mixture of protease
inhibitors. IgG antibodies from sera to be analyzed (SS and controls) were coupled to protein
A-agarose  beads  (Biozym,  Landgraaf,  The  Netherlands)  and immunoprecipitations  were
carried out as described by Raijmakers and colleagues17.
Hanover ELISA confirmation
Another way to confirm our ELISA results was to compare our data with those obtained with
the Hanover ELISA developed by Witte and colleagues12. A blinded set serum samples was
therefore analyzed in Hanover.
RESULTS
Analysis for anti-alpha-fodrin, anti-SS-B, and anti-SS-A by ELISA
Using  the  purified  alpha-fodrin–GST  protein  encoded  by  the  cDNA  construct
obtained from Dr Hayashi, we developed an ELISA (hereafter referred to as the
Nijmegen  ELISA)  that  was used  for  the analysis  of  SS and  control  sera.  The
Nijmegen IgA ELISA test  appeared to  be reasonably  specific.  Only  one serum
positive for anti-alpha-fodrin was found among the 12 RA sera. In the 28 NHS sera
and 12 sera from SLE and SSc patients, no IgA anti-alpha-fodrin antibodies were
detected. In the IgG ELISA, however, six RA sera were positive; the other control
sera (NHS, SLE, and SSc) were negative. Of the 21 sera from primary SS, 10 were
found positive the IgG ELISA, indicating a disease sensitivity of  IgG antibodies
against alpha-fodrin of 48%. Nine (43%) of the 21 primary SS sera were found to
contain  IgA  antibodies  against  alpha-fodrin  (Table  1)  and  3  (14%)  of  the  21
contained IgM antibodies against alpha-fodrin (not shown). Five the nine primary
SS  sera  with  IgA  antibodies  to  fodrin  also  contained  IgG  antibodies  directed
against this antigen. To be sure that the antibodies measured were directed against
the fodrin part of the fodrin–GST fusion protein, the ELISAs were also carried out in
the presence of 10-fold excess of purified GST protein. Essentially the same results
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were obtained. The same sera (blinded) were also analyzed in Hanover by Witte
and coworkers using their alpha-fodrin ELISA [12]. The Hanover results showed a
disease sensitivity of 38% for IgA and of 10% for IgG antibodies against alpha-
fodrin. Six 8 sera from primary SS that were positive in the Hanover IgA ELISA
were also positive in the Nijmegen ELISA, so that 6 of 21 sera from primary SS
(29%) conclusively seemed to contain IgA antibodies directed against alpha-fodrin.
While the data for IgA-positive sera from both ELISAs were quite congruent, data
for IgG-positive sera showed clear discrepancies (Table 1). We do not know why.
We also looked for the classic anti-SS-B and anti-SS-A autoantibodies in the 21
sera from primary SS. Fourteen sera contained anti-SS-A antibodies (sensitivity
67%) and 13 sera contained anti-SS-B antibodies sensitivity 62%). These activities
were confirmed by least one other technique (immunoblotting and/or precipitation).
anti-SS-B and anti-SS-A activities were absent all control sera that were included in
this study (data shown). There was also considerable overlap between presence of
anti-alpha-fodrin and anti-SS-A or anti-SS-B. Of IgA-positive sera from primary SS,
6 contained anti-SS-A and 5 contained anti-SS-B, while of the 10 IgG-positive sera,
all contained anti-SS-A also and 7 contained anti-SS-B antibodies (Table 1). Four
of  six sera from patients with secondary SS contained IgA and IgG antibodies
against alpha-fodrin. Three sera also contained anti-SS-A and anti-SS-B antibodies
Table 1). From these results we conclude that alpha-fodrin antibodies are present
in SS sera and that majority of these antibodies are of the IgG and IgA class, but
that  their  frequency in SS sera is not  higher  than of  the classic autoantibodies
directed against the Ro60 and La antigens.
Analysis  for  anti-alpha-fodrin  antibodies  by  western  blotting  and
immunoprecipitation
We also analyzed the sera for anti-alpha-fodrin antibodies by two other techniques
(immunoblotting  and  protein  immunoprecipitation)  to  confirm the  ELISA results.
general, these two techniques appeared to be less suited for this purpose. The size
of  the antigen (250 kDa) and limited presence in  cultured cells  precluded both
efficient  blotting and efficient  labeling by  35S-methionine.  There were also some
background problems that in some cases made it difficult to distinguish between
positive and negative sera. We therefore decided to count  only those that were
clearly  positive.  Of  the  sera  from  primary  SS,  five  appeared  to  be  positive
immunoblotting and four precipitated a protein with expected molecular weight of
fodrin. Two of those immunoprecipitated fodrin were also positive immunoblot, and
three also contained IgA and/or IgG antibodies  to  alpha-fodrin as measured by
ELISA (Table 1).  The presence of anti-fodrin antibodies in four sera patients with
secondary  SS  was  confirmed  immunoblotting  (four  of  four)  and  by
immunoprecipitation (three of  four)  (Table  1).  The use of  apoptotic  extracts  (to
increase amount of antigenic fodrin cleavage product) did in our hands not improve
the suitability of these techniques for the detection of anti-alpha-fodrin antibodies
(data not shown).
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DISCUSSION
The  presence  of  anti-SS-A  and  anti-SS-B  autoantibodies  has  been  part  of
Sjögren’s syndrome (SS) classification criteria including the recently established
US-European consensus group criteria, in which they play a more significant role
than before5. In the US/Eur classification criteria the presence of either anti-SS-A or
anti-SS-B  autoantibodies  or  a  positive  salivary  gland  biopsy  (LFS>=1.0)  is
mandatory for the classification of  SS. The disease sensitivity of anti-SS-A and
anti-SS-B  autoantibodies  has  been  reported  to  be  60-75  %  and  30-50  %
respectively6-9, whilst disease specificity of particularly anti-SS-B autoantibodies is
generally  considered  as  reasonably  high.  anti-SS-B  autoantibodies  are  mostly
found in  SS and SLE patients,  and  rarely in  other diseases or  normal  healthy
subjects.  Nevertheless,  there is certainly a need for a SS specific autoantibody
showing a better disease sensitivity and specificity profile.
Haneji  et  al. suggested the presence of anti--fodrin autoantibodies as a highly
specific diagnostic marker for SS. In their initial paper they reported that 96% of
primary SS sera reacted with  -fodrin10. In follow-up studies however,  they also
noticed  the  presence  of  these  autoantibodies  in  SLE  patients11.  Witte  and
collaborators showed a much lower disease sensitivity of 64% and 47% in primary
and secondary Sjögren’s syndrome, respectively, when focussing on IgA antibodies
against  -fodrin  rather  than  IgG  antibodies12.  Their  data  suggest  a  sensitivity
similar to that of anti-SS-A antibodies. However, Witte and co-workers also noticed
two positive sera in RA patients without sicca symptoms, and one positive serum in
the SLE group. These results indicate that also the disease specificity of anti--
fodrin antibody might be lower than reported previously. In our cohort of primary SS
patients, the ELISA tests of 21 sera showed a sensitivity of 43% for IgA antibodies,
and  48%  for  IgG  antibodies  against  -fodrin  which  is  comparable  to  the
percentages reported by Witte and co-workers. In the blinded set of control sera
analyzed in Nijmegen and Hannover, no positives were found in the NHS, SLE or
SSc  sera,  suggesting  that  the  ELISA  tests  in  both  laboratories  are  specific.
However, of the 12 RA sera tested in Hannover, 4 RA sera came out as positive in
the IgA-ELISA, including the one RA serum that was also positive in Nijmegen. Six
RA sera were positive in the IgG-ELISA in Nijmegen; 3 of them also in the IgG
ELISA of Hannover. These data, together with the previously reported positive RA
sera by Witte and co-workers, indicate that the presence of anti-fodrin antibodies in
a significant number of RA patients can not be ruled out. Although in this study
disease specificity  was not  evaluated against  a large variety  of  disease control
sera, these results suggest that the disease specificity of anti-fodrin antibodies is
unlikely to exceed that of anti-SS-B antibodies which are almost exclusively found
in either SS or SLE sera.  This study also showed that  there are discrepancies
between  the  two  anti-fodrin  ELISA  systems.  An  explanation  of  this  imperfect
reproducibility between the two laboratories might be that the titers of anti--fodrin
antibodies in patient sera were generally low in both ELISA systems. This makes
that  small  changes  in  the  protocol  become  important  for  the  outcome.  These
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observations underline once more the importance of an easy-to-perform alternative
biochemical  technique  to  confirm  ELISA  data19.  Based  on  the  difficulties
encountered  in  this  study  to  confirm  the  presence  of  anti-fodrin  antibody  via
alternative  techniques,  it  is  questionable  whether  anti-fodrin  antibodies  should
substitute for the classical anti-SS-A and anti-SS-B antibodies in the classification
criteria of SS. All anti-SS-A and anti-SS-B activities in our sera detected by ELISA
could be confirmed using alternative biochemical  techniques.  Besides  that,  the
observed sensitivity of these classic autoantibodies is higher than that of anti--
fodrin  antibodies,  regardless  of  the  anti-fodrin  ELISA system (Hannover  versus
Nijmegen ELISA) that was used In addition, a considerable overlap between the
presence of anti-SS-A/anti-SS-B antibody and anti- fodrin antibody was observed.
A potential  contributing role  for  anti-fodrin  antibody  measurement to  detect  SS
patients  that  are  negative  for  anti-SS-A and  anti-SS-B autoantibodies  appears
therefore unlikely.
Based on the lower frequency, as compared to anti-SS-A and anti-SS-B, and the
questionable specificity, we conclude that testing for anti--fodrin antibodies does
not have much additional value for the diagnosis of Sjögren’s syndrome.
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ABSTRACT
Sjögren’s syndrome (SS) is considered an autoimmune exocrinopathy of unknown origin,
predominantly affecting salivary and lacrimal glands. Cutaneous exocrinopathy is presumed
to account for the frequently reported xerosis in SS. Although SS predominantly  affects
women, no direct estrogen mediated pathophysiological mechanisms have been identified in
previous studies. Estrogen-beta (ERß) receptor is the predominant ER in normal skin and
salivary glands and has not yet been evaluated in SS patients specifically. The aims of this
study were to explore skin biopsy specimens of SS patients for signs of exocrinopathy and to
describe estrogen-alpha (ER) and estrogen-beta (ERß) receptor expression in the skin and
salivary  glands  of  SS patients  as  compared to  that  of  normal  healthy  subjects  (NHS).
Sublabial  minor  salivary  gland  biopsy  specimens  and  skin  biopsy  specimens  of  17  SS
patients  and  5  NHS  were  examined  for  presence  of  lymphocytic  infiltrates  and
immunohistologically analysed for ER  and ERß expression. All SS patients (12 primary, 5
secondary SS) fulfilled the American-European Consensus Group classification criteria for
SS. ER  expression was assessed using the  1D5 monoclonal antibody (Dakocytomation,
High Wycombe, UK); for  ERß detection the  14C8 monoclonal antibody (Genetex, AbCam,
Cambridge, UK) was used.  None of the 17 SS skin samples showed signs of inflammatory
exocrinopathy.  In  both  skin  and  salivary  gland  samples  ERß was  the  predominant  ER
subtype. In skin samples ER expression did not differ between NHS and SS patients. In the
salivary gland samples of all NHS and 8 SS patients a focal weak nuclear staining of ERß
was  observed.  However,diffuse  intense  nuclear  staining  (n=4)  and  focal  predominantly
cytoplasmatic  staining  (n=5)  were  also  observed  in  SS samples.  Interestingly  in  5  SS
patients some infiltrating lymphocytes in the salivary gland tissue also stained positive for
ERß.  ER  was  poorly  expressed  in  all  examined  tissues.  Evidence  for  inflammatory
cutaneous exocrinopathy in SS was not found. In SS patients ERß is the predominant ER in
skin and salivary gland tissue The observed differentiated ERß expression and the presence
of ERß positive lymphocytes within the salivary gland infiltrates in SS patients may reflect a
role for ERß in the pathogenesis or maintenance of SS.
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INTRODUCTION
Sjögren’s syndrome (SS) is considered a chronic autoimmune exocrinopathy, mainly
involving salivary and lacrimal glands, but also affecting other exocrine glands e.g. in
the upper airways, the vagina and possibly in the skin. SS is clinically characterised by
sicca symptoms such as  dry eyes and mouth. Infiltrating lymphocyte aggregates seen
in biopsy specimens of sublabial minor salivary glands, form one of the hallmarks in
the current American-European Consensus Group (AECG) classification criteria for
Sjögren’s syndrome1. Similar histological characteristics have also been observed in
lacrimal  gland  tissue2.  Although  the  majority  of  sublabial  salivary  gland  biopsy
procedures are without complications post-biopsy neuropathy reflected by localised
numbness can occur3. Also some patients may feel uncomfortable towards intraoral
invasive  procedures.  Theoretically  a  diagnostic  skin  biopsy  might  serve  as  an
alternative to salivary gland tissue biopsy in SS patients if similar histopathological
findings could be found in  cutaneous exocrine glands. Since xerosis (dry skin) is
frequently reported in SS,  an underlying cutaneous exocrinopathy, similar to salivary
and lacrimal gland tissue exocrinopathy, is presumed in textbooks of rheumatology4.
However,  in  contrast  to  salivary  gland  tissue,  few  studies  have  been  conducted
regarding  histological  changes  in  the  skin  of  SS patients.  Perivascular  infiltrates
reflecting some degree of vasculitis as a systemic manifestation of SS are the most
frequently reported histopathological finding in the skin of SS patients. Pure cutaneous
exocrinopathy   reflected  by  periglandular  lymphocytic  infiltrates,  such  as  seen in
salivary gland tissue, has only been documented in a few case reports published over
the last decennia5-10. Cutaneous exocrinopathy could be located in sebaceous glands
as  well  as  eccrine  or  merocrine  (formerly  known  as  apocrine)  sweat  glands.
Merocrine sweat glands, present in the axillae and anogenital area, are known to
be  under  the  control  of  sex  hormones.  More  recently  presence  of  sex  steroid
receptors has also been noticed in eccrine sweat glands11. 
The sebaceous glands constitute the other exocrine component of human skin. The
sebum, rather than sweat, controls moisture loss from the epidermis. Decreased
sebaceous gland function is therefore reflected in xerosis which might also be a
constituent  of  the  sicca  complex  in  SS.  Estrogens  have  a  profound  effect  on
sebaceous gland function which is opposite to that of androgens. In both sexes,
estrogen  administration  decreases  the  size  of  the  sebaceous  glands  and  the
production of sebum. Thus,  sex steroids are clearly involved in cutaneous exocrine
gland functioning (both sweat and sebaceous glands). The tissue-specific distribution
of sex steroid receptors has recently been further explored following the discovery of a
second type of estrogen receptor (ER)12. A series of reports on different localizations
and functioning of the two distinct subtypes, ER and ERß,  in human tissues has
meanwhile  become available.  ERß appears  to  be  the  predominant  ER  in  skin,
salivary glands, lacrimal glands and oral epithelium11,13,14. In literature these tissues
are referred to as 'non-classic targets' because sex steroids are thought to act on
the reproductive organs. However, it should be noted that in SS the same tissues
constitute  the  disease-specific  target  organs  in  which  exocrinopathy  becomes
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manifest.  Since  Sjögren’s  syndrome,  like  e.g.  SLE,  is  a  disorder  predominantly
affecting women, a  role  for sex steroids in the pathogenesis has been assumed
before.  Thus, the tissue-specific distribution of sex steroid receptors might provide
clues  to  the  mechanism  of  exocrinopathy  in  SS  patients.  Kassi  and  colleagues
recently reported presence of ER and splicing variants of ER in cultured epithelial
cells from salivary glands of SS patients, but also in normal health subjects (NHS)
(which has been previously described). ERß presence was reportedly not evaluated in
their study15. To our knowledge the expression of both ER and ERß receptor in skin
and salivary gland tissue has not yet been studied in SS patients specifically. 
This study was aimed to examine skin biopsy specimens of SS patients for signs of
cutaneous exocrinopathy and to describe the expression of ER and ERß in skin and
salivary gland biopsy  specimens of  SS patients.  We hypothesized that  a  distinct
expression pattern of ERß receptors in skin or salivary gland tissue of SS patients as
compared to NHS might be present and if so, might attribute to decreased exocrine
gland function in SS patients.
PATIENTS AND METHODS
Patients and biopsy sampling
After informed consent, excision biopsy was performed in the lower back of 17 SS
patients, all fulfilling the AECG classification criteria1. Lower back excision biopsy was
chosen in order to obtain skin biopsy specimens containing a sufficient amount of
sebaceous as well as sweat glands (located deep in the dermis). Previously taken
salivary  gland biopsies  of  the same patients  as  well  as  skin  and salivary  gland
samples  of  5  normal  healthy  subjects (NHS) were also included for ER subtype
expression analysis. A total of 12 patients had primary SS, whereas 5 had overlap
syndromes (2 with SS/systemic sclerosis, 2 with SS/systemic lupus erythematosus, 1
with SS/rheumatoid arthritis)(Table 1). From all paraffin-embedded biopsy specimens
eight serial  sections  (4 8m)  were examined for presence of lymphocytic infiltrates.
The  biopsy  specimens  were  then  further  processed  to  evaluate  ER and  ERß
presence as described below.
Antibodies and Immunohistochemistry
Serial sections (4 8m) were mounted on Superfrost slides and dewaxed. The sections were
blocked for endogenous peroxidase activity with 0,3% H2O2/PBS for 30min. Sections were
then subjected to heat-mediated antigen retrieval in 0.01M citrate buffer, pH6.0, for 13min
(ER) at 750w in microwave. Sections were allowed to cool undisturbed to approximately 37
degrees Celsius over the next 20min, washed (5min each) in PBS. After cooling whilst in the
buffer solution (20 min) sections were washed in PBS. The sections were then incubated
with the established 1D5 monoclonal antibody diluted 1:200 (ER,  Dakocytomation, High
Wycombe,  UK)  and  14C8  monoclonal  antibody  diluted  1:100  (ERß  Genetex,  AbCam,
Cambridge, UK) in PBS for 30min. Sections were then washed in PBS. Bound antibodies
were visualized using Powervision (ready to use, Immunologic, 30 min) and, after washing
again  in  PBS,  Powervision  diaminobenzadine  (DAB)  plus  (Immunologic,  5  min).  After
washing the sections again in PBS nuclear staining was performed using hematoxyline (1
min) followed blue-dying in by running tap water for 10 min. Sections were then dehydrated
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and permanently mounted using DEPEX mounting medium. Female breast tissue samples
were used as an external control for both antibodies.
TABLE 1 : a selection of patients characteristics grouped by ERß staining
pattern types
staining type n pSS/sSS SS-A SS-B RF igG note
diffuse intense nuclear
1 pSS + + - + polyneuropathy
2 pSS + + + + Hashimoto thyroiditis
3 pSS - - + - Klinefelter's, cerebral vasculitis
4 SS/SLE + + - + serositis
focal cytoplasmatic
1 pSS + + + +
2 pSS + + + +
3 pSS + + + -
4 SS/SLE + + + +
5 SS/SSc - - + -
focal weak nuclear  
1 pSS - - + -
2 pSS - - + -
3 pSS - - + +
4 pSS - + + +
5 pSS - - + -
6 pSS + + + -
7 SS/SSc + + - +
8 SS/RA - - + +
RESULTS
Skin biopsy specimens
No mononuclear cell infiltrates were seen in serial sections of paraffin-embedded
skin biopsy samples of SS patients or NHS. In both SS and NHS skin samples
ER was poorly expressed, being restricted to staining of some sebocytes in the
basal  layer of  sebaceous glands.  Furthermore in  eccrine sweat glands  minimal
staining for ER was only observed in two SS skin samples. In contrast,  ERß was
much more widely  expressed throughout the different  skin layers.  Nuclear  ERß
staining was found in all layers of the epidermis as well as in eccrine sweat glands
and some hair follicles. The ERß staining pattern in SS skin tissue, which varied in
intensity from weak to strong, did not differ from that of NHS samples (Figure 1A,
1B). 
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FIGURE 1A -- SKIN – SJÖGREN’S SYNDROME
FIGURE 1B -- SKIN – NORMAL HEALTHY SUBJECT
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FIGURE 1C -- SALIVARY GLAND – SJÖGREN’S SYNDROME 
diffuse intense nuclear ER-beta staining
FIGURE 1D -- SALIVARY GLAND – SJÖGREN’S SYNDROME
focal weak cytoplasmatic ER-beta staining
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Sublabial minor salivary gland biopsy specimens
Previous  diagnostic  findings  showed  a  focus  score  >  1,  i.e.  more  than  one
mononuclear cell infiltrate containing at least 50 inflammatory cells per 4 mm2, in all
salivary gland samples of SS patients. In contrast, the focus score of NHS samples
was < 1.0 (range 0-0-4). Furthermore, previously performed immunohistochemical
examination of these samples showed a percentage IgA containing plasma cells <
70  in  SS  patients  only,  which  underlined  that  these  were  well  defined  SS
patients16,17.
In  concordance with  the  findings  in  skin  tissue,  ER was  poorly  expressed in
salivary gland samples, being restricted to nuclear staining of a few ductal cells.
Again, the  ERß subtype was much more widely expressed. Three different  ERß
staining  patterns  in  terms  of  distribution,  intracellular  localization  and  staining
intensity,  ware  observed  in  SS  salivary  gland  samples.  The  samples  of  4  SS
patients  showed  a  diffuse  and  intense  nuclear  staining  in  sero-mucous  units
(Figure  1C),  whereas  samples  of  5  other  SS  patients  showed  a  focal,
predominantly  cytoplasmatic  staining  in  sero-mucous  units  (Figure  1D).  The
remaining 8 samples of SS patients showed a pattern comparable to the pattern
observed in NHS, with focal weak nuclear staining of sero-mucous units (Figure
1E).  No commonly shared clinical or serological features were identified in those
patients that showed the same type of ERß staining pattern. Also the ERß staining
pattern was not sex-related. The distinct staining patterns of sero-mucous units was
accompanied by sporadic weak staining of ductal cells in all examined specimens.
Interestingly we coincidentally noted that in the samples of 5 SS patients staining
for  ERß  was  also  positive  in  10-30%  of  the  lymphocytes  present  within
plasmalymphocyitic infiltrates (Figure 1F). We did not identify a commonly shared
clinical feature in those patients that showed a markedly increased nuclear  ERß
staining pattern or ERß positive lymphocytes.
DISCUSSION
In this study a  predominance of ERß expression, as compared to ER, was found
in  skin and salivary gland biopsy samples of SS patients. This is in line with the
previously described predominance of ERß in skin and salivary glands of NHS. Skin
samples of both NHS and SS patients showed similar ER and ERß staining patterns
and a total absence of periglandular lymphocytic infiltrates. By examining eight serial
sections of each biopsy specimen the risk of missing an infiltrate (sampling error) was
minimized. Thus, in concordance with previous study results, a skin biopsy does not
appear to provide an alternative for salivary gland biopsy in the diagnosis of Sjögren’s
syndrome.  Based  on  these  study  results,  (immuno)histological  evidence  for  the
presence  of  cutaneous  exocrinopathy  in  SS  is  still  lacking.  Therefore,  from  a
pathophysiological point-of-view, xerosis (dry skin) can currently not be considered a
constituent of the sicca complex in SS.
In salivary gland specimens of SS patients three distinct ERß staining patterns were
noticed. These staining patterns differed from each other in  intensity as well as in
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localization of ERß staining. One of these three patterns was similar to that of NHS.
To our knowledge, although ERß positive lymphocytes have recently been reported in
human secondary lymphoid tissues18, the observation of ERß positive lymphocytes
within the focal sialadenitis infiltrates in SS patients has not been described before. It
will be challenging to further elucidate the function and relevance of the observed ERß
expression patterns and ERß positive lymphocytes in salivary  gland tissue of  SS
patients. For this purpose selective estrogen receptor modulators (SERMs) may offer
an interesting study tool.
Since Sjögren’s syndrome, like e.g. SLE, is a disorder predominantly affecting women,
a role for sex steroids in the pathogenesis has been assumed before. Reports of both
beneficial and adverse effects of estrogen-replacement therapy on the course of SS
or SLE provide additional support for this hypothesis. Interestingly, estrogen activity
has also been linked to cutaneous expression of the classical Sjögren’s syndrome
related antibodies anti-SS-A and anti-SS-B, which are also found in SLE patients.
Estradiol has been reported to enhance binding of antibodies specific for SS-A and
SS-B to cultured human keratinocytes19-23.  It  must  be noted that  all  studies  were
performed in vitro in an experimental setting using cultured cells.
Estrogens have been reported to exert complex tissue-specific effects24. The same
stimulus thereby leads to a different response in ER cells compared to ERß cells.
ER is almost always an activator, whereas ERß can inhibit the action of ER by
forming a heterodimer with it25. Moreover, microarray analysis in mice with deletions
of  ER or  ERß has shown that  ERß can inhibit the transcription of 240 estrogen-
responsive genes by 46 percent26.  The relative levels of expression of these two
receptor isoforms will therefore affect the cellular responsiveness to estrogens27,28.
Thus, the observed variations in ERß expression within SS patients might  offer an
explanation for the conflicting data of estrogen-replacement-therapy  in SS29,30,31.
ERß may  hypothetically  also  act  as  an  anti-androgen,  thereby  supporting  a
hypothesis put forward by others that women with SS may be androgen deficient32.
In conclusion in this study no (immuno)histological evidence was found to support
the hypothesis  that  xerosis  in  SS patient  results from an underlying cutaneous
exocrinopathy. Furthermore, we have demonstrated that ERß is the predominant ER
in salivary  gland and skin  tissue of  SS patients,  which is  in  concordance with
previous  findings  in  NHS.  However,  in  SS  patients  ERß expression in  salivary
glands was found to differ significantly from NHS and between patients. In addition,
in  SS  patients  ERß-positive infiltrating  lymphocytes  can  be  found  in  the
characteristic focal sialadenitis lesions. Further studies should point out  whether
this differentiated  ERß expression is of  pathophysiological  relevance.  If so, new
pathophysiological and therapeutic concepts for SS may be developed by using
SERMs.
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FIGURE 1E -- SALIVARY GLAND – SJÖGREN’S SYNDROME
focal weak nuclear ER-beta staining
FIGURE 1F -- SALIVARY GLAND – SJÖGREN’S SYNDROME
ER-beta staining of infiltrating lymphocytes
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ABSTRACT
Objective: 
Increasing the accuracy of the diagnosis of Sjögren’s syndrome (SS) by putting emphasis on
objective findings such as presence of Ro- and La autoantibodies and abnormal salivary
gland tissue (SGT) histology is a current issue. In order to obtain optimal disease-sensitivity
and specificity of SGT findings histological and immunohistological SGT examination were
compared. The first describes the extent of the lymphocytic infiltrate as a focus-score (LFS),
whereas the latter describes the composition of the infiltrate as a percentage IgA-containing
plasmacells (IgA%). 
Methods: 
Both LFS and  IgA% scores were  assessed in 279 SGT biopsies taken of  patients with
symptoms  suggestive  for  SS.  In  case  histological  conclusions  did  not  match  with
immunohistological  conclusions  patients  were  assigned  to  so-called  mismatch  groups.
Patients  in  the  mismatch  groups  were  further  classified  using  objective,  serological
parameters (RF, anti-SS-A, anti-SS-B, ANA, gammaglobulin level).
Results: 
In 249 samples (89%) LFS and IgA% resulted in the same conclusion. Within this group a
total of 63 SGT samples (25%) were characteristic for SS showing LFS >1.0 and IgA% <70.
In the mismatch groups after serological classification both false positive as well as false
negative scores were observed less frequently for IgA% as compared to LFS (50% versus
75% and 25% versus 50% respectively). 
Conclusions: 
Additional  immunohistological  SGT  examination  provides  higher  disease  sensitivity  and
specificity  than  histological  SGT  examination  alone,  thereby  increasing  accuracy  of  SS
diagnosis.
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INTRODUCTION
Sjögren’s  syndrome  (SS)  is  a  chronic  autoimmune  exocrinopathy  of  unknown
origin. Therefore the diagnosis of SS, in the absence of a golden standard is based
on criteria containing a number of subjective and objective symptoms and signs. In
the past three decades several sets of criteria have been introduced1-4. In recent
criteria sets it is noteworthy that more weight is put on objective than subjective
findings such as dry eyes or dry mouth.  This shift towards objective findings is
partly based on the fact that in an era of computers and dry working places the
frequency of dry eyes or dry mouth complaints increases. As these symptoms are
part of the currently used criteria, the number of false-positives increases. When
the presence of anti-SS-A- and anti-SS-B autoantibodies, as well as on a sublabial
salivary  gland  tissue  (SGT)  biopsy  focus-score  (LFS)  >1  is  emphasised,  by
requiring presence of both of these objective pathophysiological signs, the number
of  false-diagnosed SS patients will  reduce considerably.  If  the European Study
Group (ESG) classification criteria1 are modified in this way the prevalence of SS in
European countries is expected to lower from 1-3% to about 0.5 %. The prevalence
of SS in Europe would then be similar to the proportion diagnosed with San Diego
or San Francisco criteria applied in  the US5.  However,  when a greater value is
attributed  to  SS-A-  and  SS-B-autoantibodies  and  SGT  biopsy,  the  disease-
sensitivity and disease-specificity of each of these objective parameters becomes
more important and should be reconsidered. The focus score, based on the extent
of the lymphocytic infiltrate in SGT biopsy, is the most used objective target-organ
specific sign in the diagnosis of SS. It is also the only histological parameter named
in the current classification criteria. It is generally considered that a focus score >1
is strongly associated with SS. But meanwhile several reports have shown that a
focus  score  >1 can  also  be found  in  other  systemic  disease  (e.g.  rheumatoid
arthritis (RA), lupus erythematodes disseminatus, primary biliary cirrhosis, AIDS,
myasthenia  gravis,  graft-versus-host  disease)  as  well  as  in  5-10%  of  normal
healthy subjects, thereby reducing its disease-specificity for Sjögren’s syndrome6-8.
More recently it was shown that a potential negative influence of external factors
like smoking and use of medication on the number of foci  cannot be ruled out,
thereby  reducing  the  sensitivity  of  the  focus  score9,10.  Therefore  additional
examination of the SGT might help to differentiate between true- and false positive
and  negative  focus  scores.  One  of  the  methods  to  do  so  is  quantitative
immunohistological (QIH) examination of the SGT biopsy. Here the composition of
the lymfocytic infiltrate is described in terms of immunoglobulin subtypes (IgG, IgM,
and IgA). In the QIH criterion introduced in 1982 by Bodeutsch et al. a percentage
IgA containing plasma cells (IgA%) less than 70 was very specific for SS6. With the
QIH criterion some patients previously not fulfilling ESG criteria for SS because of a
focus score < 1 could be identified as having SS. Thus, when shifting towards more
objective  and  target-organ  specific  signs,  examining  SGT  biopsies
immunohistochemically instead of or next to histologically appears favourable. The
objective  of  this  study  is  to  compare  disease-sensitivity  and  –specificity  of
histological  (focusscore)  results  to  immunohistological  (IgA%)  results  from
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examination of SGT biopsies to evaluate both methods which have been part of
routine examination of SS in our department for over 10 years now.
METHODS
From 1988-1998 a total of 279 SGT biopsies were taken of patients with symptoms
suggestive for  SS. Both LFS and IgA% scores  were assessed in  the biopsies.
Samples were assigned to one of four groups: a group with LFS>1.0 and IgA%<70
(i.e.  histological  diagnosis  ‘SS’),  a  group  with  LFS<1.0  and  IgA%>70  (i.e.
histological  diagnosis  ‘no  SS’),  and  two  mismatch  groups  A  and  B.  Group  A
consisted of  samples with LFS>1.0 and IgA%>70 and group B of samples with
LFS<1.0 and IgA%<70. The mismatch groups A and B were further classified using
the  following  major  and  minor  objective  serological  criteria:  elevated
gammaglobulin  level  and  presence  of  SS-A-  and  SS-B-autoantibodies  were
considered major objective parameters suggesting SS, whereas presence of RF or
ANA were considered minor objective parameters suggesting SS. If  both major
parameters were present, or if one major plus one minor parameter were present,
the mismatch patient was considered as having SS. Instead, if patients had only
minor  criteria,  they  were considered as  having (secondary)  sialadenitis  but  not
Sjögren’s syndrome. In the double positive or double negative concordant biopsies
groups the  number  of  false  positive and false  negative  LFSs  and  IgA%s was
estimated based on the oldest half (first five years) of data (n=149). Since these
biopsies showed concordant immunohistological results,  not  only the serological
classification criteria used in the mismatch groups but also the current ESG criteria
could be used in these groups, enabling comparison of both definitions.
RESULTS
Of  the  279  biopsies  63  showed  a  LFS  >1  and  an  IgA%<70  which
immunohistologicallly classified these patients as having SS. A total of 186 biopsies
showed an LFS <1 and an IgA%>70 which led to the immunohistological diagnosis
‘no SS’. Furthermore 16 biopsies (group A) showed a LFS >1 and an IgA%>70,
and 14 biopsies (group B) showed a LFS <1 and an IgA%<70. Thus the diagnosis
based on the two different histological criteria did not match in 30 of 279 biopsies
(11%). Additional serological analysis (using the major and minor objective criteria
as described in the Methods section) of these two “mismatch” groups classified 12
out of 16 positive LFS (75%) and 7 out of 14 (50%) positive IgA% scores as not
having SS. Vice versa, based on the serological classification criteria, 4 out of 16
(25%) negative IgA% scores and 7 out of 14 negative LFS (50%) could still  be
classified as having SS. (Tables I,III).
In  the further analysed double positive concordant  group (n=31)  71% could be
classified as having SS when applying the current ESG classification criteria. The
remainder 29% strictly spoken does not have SS but has a (immuno-)histological
picture which is strongly suggestive for  SS. Of this latter group (n=9)  44% has
SS-A/SS-B presence and therefore are positive for two objective and most 
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TABLE I - Characteristics of patients in mismatch groups
Initials Age Sex Ro La Gam.Glob RF ANA Comorbidity LFS IgA% SS?
LFS >1 and IgA% >70 (mismatch group A)
1 G. K. 72 F - - 6.2 - + RA 1.8 72.6 No
2 R. B. 54 F - - 7.5 + + RA 2.3 82.8 No
3 V. W. 55 F - - 17.1 - + UCTD 1.1 84.9 Yes
4 J. K. 55 F - - 10.8 - + Sicca syndrome 1.2 79.0 No
5 H. P. 72 F - - 12.0 + + RA 3.2 72.8 No
6 B. T. 62 F - - 9.1 - - RA 2.1 86.4 No
7 Z. 47 M - - 12.2 + + RA 1.4 95.7 No
8 D. 72 F - - 12.6 + + RA 1.7 87.5 No
9 V. 67 F + + 12.2 + + 2.2 72.6 Yes
10 H. 72 F - - 19.6 + + RA 1.7 77.9 Yes
11 G. 69 M - - 12.7 + + UCTD 1.2 74.9 No
12 J. 49 M - - 13.4 + - RA 1.0 84.2 No
13 B. V. 48 F + + 18.6 - + 1.0 72.9 Yes
14 W. I. 50 F - - 9.6 - + SLE 1.7 81.5 No
15 B. 69 F - - 15.1 - + 4.7 77.0 No
16 W. E. 65 F - - 7.5 - + 1.9 77.5 No
LFS <1 and IgA% <70 (mismatch group B)
1 C. 78 F + + 20.0 + - RA 0.9 23.9 Yes
2 D. 31 F - + 22.8 + + SLE 0.8 58.9 Yes
3 M. 65 F - - 12.7 - + Raynaud 0.8 69.3 No
4 W. E. 83 F - - 11.8 + - RA 0.7 27.9 No
5 V. S. 42 F - - 9.4 - - 0 65.5 No
6 G. 50 M + + 17.4 + + 0 66.6 Yes
7 V. O. 45 F + + 16.4 - + Scleroderma 0 67.5 Yes
8 L. 52 M - - 8.3 - + Sicca syndrome 0 49.2 No
9 D. I. 50 F - - 11.2 + - Fibromyalgia 0 69.0 No
10 E. 50 M + - 10.0 - + 0 57.1 Yes
11 B. E. 34 M - - 17.2 - + 0.9 64.7 Yes
12 B. R. 43 F - - 8.1 - + 0.2 60.5 No
13 W. 48 M - - 7.4 + - RA 0.3 66.2 No
14 S. J. 33 F + - 18.2 - + 0.8 69.4 Yes
M, male; F, female; Ro, La, RF, ANA: +, positive, -, negative; UCTD, undefined connective tissue
disease; SLE, systemic lupus erythematodes; SS, Sjögren's syndrome, classified according to
serological criteria. Gam.golb, Gammaglobulin (level >15.5 g/l is considered as elevated).
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diseasespecific  parameters.  In  the  double  negative  group  (n=90),  which  as  a
consequence already lacks one of 6 items (no LFS>1), 31% fulfilled 3 out of 6
items  (oral  and  ocular  sicca  symptoms,  ocular  sicca  signs)  of  the  ESG
classification  criteria,  but  only  one  patient  fulfilled 4  out  of  6  items,  leading to
diagnosis SS (Tables II, III). 
TABLE II - Characteristics of patients in concordant groups
n
Oral sicca
(%)
Ocular sicca
(%)
Ocular test
(%)
Ro/La
(%)
ANA
(%)
RF
(%)
Gamma
(%)
SS
(%)
SS (4+)
(%)
LFS <1, IgA% >70 90 64 72 56 9 47 30 10 13 1
LFS >1, IgA% <70 31 71 61 65 48 74 71 39 61 71
ANA, the presence of anti-nuclear antibodies; RF, the presence of rheumatoid factor; Gamma, elevated
gammaglobulin level (>15.5 g/l); SS, Sjögren's syndrome, classified according serological criteria; SS
(4+), diagnosis of Sjögren's syndrome based on four positive items of ESG classification criteria.
Oral sicca: xerostomia symptoms as described in ESG classification criteria; ocular sicca: xerophthalmia
symptoms as described in ESG classification criteria; ocular test: Schirmer-I test positive (<5 mm in 5
min).
TABLE III - Serological classification overview
n SS (serological) SS (4+)
Concordant biopsies
   LFS <1, IgA% >70 90 13% (12) 1% (1)
   LFS >1, IgA% <70 31 61% (19) 71% (22)
Disconcordant biopies
   LFS >1, IgA% >70 16 25% (4) n.a.
   LFS <1, IgA% <70 14 50% (7) n.a.
SS, Sjögren's syndrome, classified according serological criteria; SS (4+), diagnosis of Sjögren's
syndrome based on four positive items of ESG classification criteria; n.a., not applicable since the
disconcordant biopsy itself is part of these criteria.
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When  applying  the  serological  criteria  that  were  used  for  classification  of  the
mismatch-groups, in the double positive group (n=31) 61% could be classified as
having SS, whilst in the double negative group (n=90) 13 %
could be classified as having SS.
DISCUSSION
In  this  analysis  of  collected  SGT  biopsy  data  the  additional  value  of
immunohistological  examination of  SGT was confirmed. When both focus-score
and IgA% are assessed,  an objective,  target-organ specific  diagnosis  could be
established in the majority (89%) of cases. However an unambiguous histological
diagnosis is not necessarily equivalent to an unambiguous clinical diagnosis, as
can be concluded from the additional analysis of concordant biopsies. Although this
analysis  showed  that  SGT  biopsy  contributes  considerably  in  distinguishing
between  SS  and  non-SS  patients,  biopsy  results  therefore  still  need  further
confirmation by e.g. serological parameters, unless a more disease specific and
sensitive tissue-marker is available.
In 11% of cases the conclusion of histological examination of SGT biopsies (focus-
score) did not match with the immunohistological result (IgA% score). In these so
called  “mismatch”  cases  the  IgA%  appears  superior  to  the  focus  score  when
objective,  serological  findings  are  taken  into  account.  After  this  serological
classification, both the numbers of false positive and false negative IgA% scores
were considerably  lower  than the numbers  of  false positive and false negative
focus scores. 
In our model chosen for the classification of the two mismatch groups serological
parameters  were  used  as  objective  decisive  data,  since  a golden  standard  to
compare the SGT biopsy results with is lacking. Furthermore none of the existing
classification-criteria  could  be  used  for  categorisation  of  patients  within  the
mismatch groups because the focus-score itself is part of these criteria. Not only
should  the model  contain  objective decisive  parameters,  it  should  also  enable
distinguishing (secondary) focal sialadenitis and secondary Sjögren’s syndrome.
The latter term should be used with caution,  i.e.  if next  to a LFS >1 additional
objective signs of  Sjögren’s syndrome are present in  a  patient  with  connective
tissue disease. Thus, a patient suffering from rheumatoid arthritis (RA), with a LFS
>1, but  no other objective signs of  Sjögren’s  syndrome should be classified as
having secondary focal sialadenitis, not Sjögren’s syndrome.
Previous findings of  different  immunohistochemic characteristics in SGT support
the need to distinguish between sialadenitis and (secondary) Sjögren’s syndrome.
The  combination  of  a  LFS>1,  combined  with  an  IgA%>70  and  a  normal  La-
expression pattern is typically observed in  sialadenitis,  as seen in  RA patients,
whereas in primary SS and secondary SS (e.g. next to RA) a LFS>1, combined
with an IgA%<70 and an abnormal SS-B-expression pattern was found, suggesting
a  different  pathogenesis11.  Furthermore  auto-immune  disease  (such  as  RA)
patients with a LFS>1 (i.e. sialadenitis) but without any signs or symptoms of SS
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have been described previously6, 7. Therefore in this model differentiation between
sialadenitis  secondary  to  RA  versus  Sjögren’s  syndrome  was  enhanced  by
attributing more value to elevated gammaglobulin-level and  presence of SS-A- and
SS-B-autoantibodies. These parameters appear to be more Sjögren’s syndrome-
specific objective parameters than RF and ANA, which are also frequently present
in  e.g.  RA patients.  This is  further  supported by  the measured percentages of
serological  markers  present  in  histological  positive  patients  as  compared  to
histologically negative patients (table II). However, the presence of SS-A- or SS-B-
antibodies is almost inevitably associated with positive ANA testing (but not vice
versa).  Therefore  applying more  strict  disease-specific criteria  in  the  model  for
categorisation of  the mismatch groups was also considered by comparing SGT
results  to  SS-A-  or  SS-B-  antibodies  presence  only.  In  Sjögren’s  syndrome
presence of these antibodies is by far the most diseasespecific serological sign to
date. When presence of SS-A- or SS-B-autoantibodies was considered as decisive
for the diagnosis of Sjögren’s syndrome, the results showed the same pattern of
false negative and false positive scores (data not shown). The conclusion remained
that the IgA% score in these cases is superior over the focus-score. However, the
latter  model  leaves  no  place  for  SS-A-  or  SS-B-autoantibodies  seronegative
Sjögren’s syndrome patients, which  are generally believed to form about 20% of
the Sjögren’s syndrome population12-15.
Should the focus score be considered as  obsolete? Our data suggest  that  the
combination of both focus-score and IgA% score can have a synergistic value for
the  accuracy  of  diagnosis.  In  cases  of  doubt,  the  other  parameter  can  direct
towards the right diagnosis. In this study the number of false negative IgA% scores
was remarkably low. An IgA% >70 in combination with a focus score >1 should
therefore be interpreted as a false positive focus  score.  The interpretation of  a
focus score <1 in combination with an IgA% <70 is less clear,  since both false
negative  focus  scores  and  false  positive  IgA%  scores  appear  to  occur  about
equally in this mismatch group. However, in the majority of cases assessment of
both focus-score and IgA% score leads to an unambiguous histological conclusion.
Nevertheless whether histological and immunohistological findings match or not,
neither of them have been shown to be 100% sensitive and specific, as was also
depicted in the analysis of concordant biopsies. Therefore these SGT parameters
should still  be related to  other  available  objective data such as  the serological
profile. An additional advantage of immunohistological examination of SGT is that
immunohistological  changes,  such  as  %IgA  containing  plasmacells,  are  not
necessarily associated with lymphocytic foci and, in contrast to histological findings,
are much more diffusely located throughout the minor salivary glands tissue6. As a
consequence the sampling error with regard to the %IgA containing plasmacells, or
other yet to develop immunohistological disease specific markers, is less than that
of the focus score.
In conclusion, immunohistological examination of SGT provides valuable additional
information and reduces sampling error thereby increasing accuracy of diagnosis.
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Thus, in order to acquire a maximum of relevant information out of the target
organs in SS histological examination of SGT only is not sufficient and should be
accompanied by immunohistological examination as well. In other words: two sub-
optimal tissue-markers in terms of disease specificity and sensitivity together
provide more sensitivity and specificity than applying only one of them.
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ABSTRACT
Sjögren’s syndrome (SS) is a chronic autoimmune disease characterised by specific lesions
in exocrine glands, so sublabial minor salivary gland biopsy (SLGB) plays an important part
in its diagnosis. The extent and composition of the lymphocytic infiltrate in SLGB specimens
can be considered as target organ specific parameters. They are quantified after histological
and immunohistological examination by a focus score (describing the extent of the infiltrate)
and IgA% score (describing the composition of the infiltrate), respectively. However, little is
known about the factors that contribute to the extent and composition of the infiltrate and
whether these features are reversible as repeated SLGBs are rarely performed. A patient
with SS is described who underwent SLGBs before and after treatment with high dose
corticosteroids. After treatment there was not only clinical improvement, but also
improvement in the histological and immunohistological parameters. Although these findings
need to be confirmed in further studies, this suggests that histopathological changes may be
reversible in SS. Furthermore, it shows that the potential effects of corticosteroid use should
be taken into account when interpreting SLGB specimens. When clinical changes do parallel
histological changes, repeated SLGBs might offer a marker for disease activity in patients
with SS.
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Sjögren’s  syndrome  (SS)  is  a  chronic  autoimmune  disease  characterised  by
specific  lesions  in  exocrine  glands1.  Salivary  and  lachrymal  glands  are  most
prominently involved in this condition, leading to organ specific symptoms such as
xerostomia and xerophthalmia.  Apart  from these local symptoms, most  patients
also suffer from systemic manifestations such as fatigue, arthralgia, and myalgia.
Furthermore,  patients  with  primary  SS—that  is,  without  comorbidity  from other
rheumatic  diseases—  have  an  increased  risk  of  developing  a  non-  Hodgkin’s
lymphoma which is 44 times greater than the rate in the general population2. 
Since  the  first  description  of  SS  by  Henrik  Sjögren,  many  criteria  have  been
proposed  for  the  diagnosis  or  classification  of  this  syndrome3–6.  Histological
examination  of  sublabial  minor  salivary  gland  biopsy  (SLGB)  specimens  is  an
important factor in these criteria. The extent and composition of the lymphocytic
infiltrate  in  the  SLGB  specimens  can  be  considered  as  target  organ  specific
parameters. The number of lymphocytic foci per 4 mm2  in the SLGB specimen is
expressed as a focus score.  However, it is well known that the focus score lacks
both sufficient  sensitivity  and specificity  for  the diagnosis  of  SS, depending on
whether a focus score of >1 (leading to decreased specificity) or >2 (leading to
decreased sensitivity) is taken as the criterion for diagnosis7–9.  In contrast to the
focus score, immunohistological  examination of the infiltrate has been shown to
have  both  high  disease  specificity  and  sensitivity7,10.  This  method  is  based  on
quantification  of  plasma  cells  expressing  different  isotypes  of  immunoglobulins
(IgA, IgM, IgG). A percentage of IgA containing plasma cells (%IgA) of less than
70, or of IgM containing plasma cells (%IgM) of more than 10, is highly specific for
SS.  So far,  little  is  known about the factors  that  contribute  to  the  lymphocytic
infiltrate.  Manthorpe  et  al  recently  reported  the  possibility  that  patients  might
“smoke” their lymphocytic infiltrate away11. In their study the focus scores found in
SLGB specimens of 355 patients with either SS or stomatitis sicca were compared
with  the smoking habits of  the patients,  and a lower  focus score was found in
patients who smoked. It appears, however, that external factors may influence the
lymphocytic infiltrate  seen in  SLGB specimens.Medication may well  be another
external factor which influences the lymphocytic infiltrate. These factors should be
taken into account when interpreting the SLGB results.
This case report describes a patient  with SS in whom changes occurred in the
lymphocytic infiltrate in the SLGB specimen after treatment with corticosteroids.
CASE REPORT
A 35 year old man with Klinefelter’s syndrome was referred with signs suggestive of
SS. He complained of dry eyes and mouth, both of which had been present for 10
months.  Shortly after onset of  the dry eyes he had started to use artificial  tear
droplets. He also suffered from fatigue and had a history of back pain and a painful
but not swollen left hand for 10 years.
For the previous 8 months he had also had a painful left knee. He did not smoke or
use any medication.  Physical examination revealed no abnormalities  other  than
71
signs compatible with Klinefelter’s syndrome (gynaecomastia and spare body hair
pattern), except for increased conjunctival injection.  Laboratory findings included
erythrocyte sedimentation rate (ESR) of 10 mm/1st h, C reactive protein (CRP) <5
mg/l, normal blood count, normal liver function tests, normal kidney function, and
slightly  raised  gammaglobulin  (16.6  g/l)  without  paraproteins  on
immunoelectrophoresis.  Further  testing  revealed  positive  antinuclear  antibody
staining on indirect immunofluorescence with  a homogeneous pattern.  Tests for
rheumatoid factor were negative. No autoantibodies such as anti-SS-A, anti-SS-B,
anti-Sm, anti-dsDNA, and anti-RNP could be detected either by immunoblotting or
by  counter  immunoelectrophoresis.  Ophthalmic  examination  revealed  a
keratoconjunctivitis  sicca  with  abnormal  rose  bengal  staining  of  the  cornea,
diminished tear drop break up time (3 seconds), and Schirmer’s test of 0 mm in 5
minutes for both eyes. Histological examination of the four glands from the SLGB
showed  1.0  lymphocyte  aggregates  per  4  mm2—that  is,  a  focus  score  of  1.0.
Quantitative  immunohistological  examination  gave  %IgA  of  64.  Based  on  the
European Study Group diagnostic criteria,  a  diagnosis  of  SS was established5.
Local treatment with eye droplets was started to treat the keratoconjunctivitis sicca.
After several weeks, however, the patient developed a painless dystonia of the left
hand, with the third to fifth finger as well as the wrist in fixed hyperflexion. The left
foot  showed a slight  inversion and internal rotation.  Serological  testing for anti-
dsDNA,  antineutrophilic  cytoplasmic,  and  anticardiolipin  antibodies  and  lupus
anticoagulants appeared to be negative. Further neurological examination showed
no  abnormalities  by  electromyography  (EMG)  or  magnetic  resonance  imaging
(MRI)  of  the  brain.  However,  single  photon  emission  computed  tomography
(SPECT)  with iodobenzamide (IBZM) labelled with  123iodine revealed decreased
uptake in the right striatum (striatum:occipital cortex ratio 1.53 on the left, 1.41 on
the right, mean normal (2SD) value 1.66 (0.16)), indicating a loss of D2 receptors in
the  right  striatum  (neurological  details  have  been  published  previously)12.  A
diagnosis  of  neurovasculitis  located  in  the  right  striatum  was  made,  and  was
considered to be an extraglandular complication of SS. Treatment with high dose
prednisone (60 mg daily) was started and within 2 weeks the dystonia and the
sicca symptoms had disappeared. Re-examination of the lachrymal glands showed
a normal Schirmer’s test (15 mm in  5 minutes for both eyes), normal tear drop
break up time, and normal rose bengal staining of the cornea. After 2 months of
treatment the medication was tapered to a dose of 30 mg/day. At that time, and
after informed consent had been obtained, a second SLGB specimen was taken to
examine  the  histological  and  immunohistological  changes  in  the  lymphocytic
infiltrate. This specimen, in contrast to that taken before treatment, showed not only
a normal focus score (0.4) but also a normal IgA% score of 80 on examination of
the four glands. Thus, in addition to an improvement in the clinical symptoms, the
lymphocytic infiltrate appeared to have normalised after corticosteroid treatment.
After 1 month, however, there was a relapse in both sicca and hand symptoms on
prednisone 30 mg daily. The dose of prednisone was increased to 60 mg daily and
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azathioprine was added to enable the corticosteroid dosage to be re-tapered. Again
the symptoms disappeared and returned after tapering of  the prednisone dose.
Azathioprine was therefore stopped and replaced with cyclophosphamide (100 mg
daily) which enabled the corticosteroid dose to be successfully tapered.
DISCUSSION
This  case  report  describes  a  patient  with  SS  complicated  by  neurovasculitis,
manifested by dystonia of the left hand and foot. After treatment with high doses of
corticosteroids,  both the sicca symptoms and the dystonia quickly disappeared.
Furthermore,  at  the  same  time  this  treatment  resulted  in  normalisation  of  the
histological  and  immunohistological  abnormalities  in  the  SLGB  specimen.  This
suggests  a relation between changes in  clinical  symptoms and histological and
immunohistological changes. Repeated SLGBs might therefore offer an objective,
target organ specific method for evaluating treatment since both the clinical and
(immuno)histological signs appear to be reversible. This is important because there
is, as yet, no clear marker of disease activity for SS and evaluation of treatment is
primarily based on subjective parameters.
The histological findings of an SLGB specimen already play an important part in
several criteria sets for SS. The diagnosis of SS was made because the patient
met the following four of  the six  ESG criteria:  the presence of  ocular  and oral
symptoms  for  more  than  3  months,  ocular  signs  (abnormal  Schirmer’s  test,
abnormal  rose bengal staining),  and a focus score of  1.0.  In the second SLGB
specimen, however, a normal focus score was observed. If this had been the initial
SLGB specimen, the diagnosis of SS would have been less likely and could have
been missed,  particularly since,  at  that  time, the sicca  signs  had disappeared.
Although the normalised second SLGB specimen might be found coincidentally as
a result of sampling error, examination of both specimens included four glands and
both samples were examined by two independent pathologists. Furthermore,
Bodeutsch et al showed that the %IgA containing plasma cells are not necessarily
associated with lymphocytic foci and, in contrast to the focally situated lymphocyte
aggregates, are much more diffusely distributed throughout the tissue of the minor
salivary  glands7.  Thus,  the  sampling  error  with  regard  to  the  %IgA containing
plasma cells is much less than that for the focus score. 
In our opinion, therefore, normalisation of both the focus score and the IgA% score
gives a reliable result. This case shows that the effect of corticosteroids on the
extent  and composition of  the  infiltrate  in  the target  organ in  patients  with  SS
cannot  be  excluded.  The  same  phenomenon  might  appear  when  other
immunosuppressive  agents  such  as  disease  modifying  antirheumatic  drugs
(DMARDs) are used. To minimise the potential bias of immunosuppressive agents,
it  is  therefore  important  to  take  the  SLGB  specimen  before  starting  anti-
inflammatory treatment. As patients with rheumatoid arthritis often also suffer from
SS,  the  possible  impact  of  treatment  with  DMARDs  or  corticosteroids  on
histological and quantitative immunohistological examination of an SLGB specimen
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should be taken into consideration in the diagnosis of SS. Since SLGB plays an
important  part  in  the diagnosis of  SS, further studies need to  be performed to
establish  which  factors  contribute  to  the  composition  of  the  infiltrate  in  these
exocrine glands. However, the suggested dynamic properties of histopathological
changes need to be confirmed in further studies.
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ABSTRACT
Objective. 
This pilot study evaluated the effect of anti-tumor necrosis factor- antiinflammatory
treatment with etanercept (Enbrel®) on sicca, systemic, and histological signs in patients
with primary Sjögren’s syndrome (SS).
Methods. 
Fifteen patients with well defined primary SS were treated with 25 mg etanercept
subcutaneously twice per week during 12 weeks, with followup visits at Weeks 18 and 24.
Evaluation measures included a Multidimensional Fatigue Inventory (MFI) questionnaire,
serological monitoring, salivary flow tests, Schirmer test, rose bengal cornea staining, and
tear film breakup time. A sublabial minor salivary gland biopsy was performed at baseline
and at Week 12 and lymphocytic focus score and percentage IgA-containing plasma cells
(IgA%) were assessed.
Results. 
No increase of salivary or lachrymal gland function was observed in any participant. In 4
patients a decrease of fatigue complaints was noted, which was also reflected by decreased
scores in the MFI questionnaire. Reduced erythrocyte sedimentation rate was observed in 3
of 4 patients with reduced fatigue. No significant change of lymphocyte focus score or IgA%
was observed. Arepeated treatment up to 26 weeks showed the same results.
Conclusion. 
A 12-week or prolonged treatment of etanercept 25 mg twice weekly did not appear to
reduce sicca symptoms and signs in SS. However, etanercept treatment may be beneficial in
a small subgroup of SS patients with severe fatigue. Etanercept 25 mg twice weekly did not
affect minor salivary gland biopsy results.
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INTRODUCTION
Sjögren’s  syndrome  (SS)  is  a  chronic  autoimmune  exocrinopathy  of  unknown
origin. As a consequence of exocrinopathy, patients present with sicca signs such
as  irritated  eyes,  a  dry  mouth,  chronic  cough,  and  dyspareunia.  Other
manifestations of SS include nonspecific systemic symptoms such as moderate to
severe invalidating fatigue, arthralgia, myalgia, and intermitting fever1. Patients with
SS have an increased risk  to  develop  non-Hodgkin’s  lymphoma,  which affects
about 5% of these patients2.
The diagnosis of SS is frequently guided by classification criteria sets. Within the
recently proposed US/European consensus group classification criteria3, objective
items such as presence of anti-SSA or anti-SSB autoantibodies and minor salivary
gland biopsy showing a lymphocytic focus score (LFS) > 1 are emphasized. In
addition  to  the  LFS,  which describes  the extent  of  a  lymphocytic  infiltrate,  the
composition of the infiltrate can also serve as a diagnostic tool. For example, the
percentage IgA-containing plasma cells (IgA%) appears to have greater disease
specificity and sensitivity than the LFS4,5. Apart from the discomfort patients with
SS  experience  from  sicca  symptoms  (e.g.,  sleep  disturbance),  the  effect  of
systemic  symptoms  is  often  underestimated.  Moderate  to  severe  fatigue  is  a
frequent complaint6 that disables a subgroup of SS patients to such an extent that it
leads to incapacity for work and limits social activities, leading to social isolation.
To date,  no effective systemic treatment is  available  for SS. Disease modifying
antirheumatic drugs (DMARD) that are successful in the treatment of several other
rheumatic diseases did not turn out to be a successful overall  approach in SS7.
Treatment is therefore mainly symptomatic and consists of artificial eyedrops and
saliva.  Pilocarpine  has  been  shown to  enhance  autologous production  of  both
saliva and tears in patients with SS8. Although some efforts were undertaken to
treat fatigue complaints using conventional or experimental drugs, none has been
proven  to  effectively  reduce  fatigue  in  patients  with  SS9,10.  Thus,  while  local
symptoms like irritated eyes and dry mouth may be alleviated to some extent, there
is neither a systemic nor a symptomatic treatment available to reduce moderate to
severe incapacitating fatigue in SS.
Recently, biological agents inhibiting the proinflammatory cytokine tumor necrosis
factor (TNF-) have been approved for the treatment of rheumatoid arthritis (RA)
and chronic juvenile arthritis11,12. Promising results have also been presented for the
efficacy of anti-TNF- treatment in psoriatic arthritis, ankylosing spondylitis,
Crohn’s disease, and Wegener’s granulomatosis13-15.
Since  enhanced  TNF- expression  has  been  observed  in  exocrine  glands  of
patients with SS16,17, anti-TNF- treatment might potentially suppress inflammation
in SS with local and systemic effects. Further, although not well documented, RA
patients  in  practice frequently  report  not  only  a  beneficial  effect  of  anti-TNF-
treatment on joint symptoms but also a marked improvement of perceived condition
and energy. A recent pilot study by Steinfeld and co-workers described treatment
with  infliximab,  an  intravenously  administered  monoclonal  chimeric  anti-TNF-
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antibody, evaluated in 16 patients with SS. Both local (reduced sicca signs) and
systemic (reduced fatigue) responses were reported18.
Etanercept  (Enbrel®),  a  soluble fully human TNF--p75-receptor  fusion protein,
also  interferes  with  the  inflammatory  process  by  binding  and  inactivating  the
proinflammatory cytokine TNF-19. Etanercept can be administered subcutaneously
by  the patients themselves.  Our pilot  study  investigated the potential  local  and
systemic therapeutic  effects  of  etanercept  in  patients  with  primary  SS. From a
diagnostic point  of view, a secondary aim of the study was to evaluate whether
etanercept treatment would influence minor salivary gland (MSG) biopsy scores.
This hypothesis was based on our observation of a normalized LFS and IgA%
following immunomodulatory treatment with high dose corticosteroids in a patient
with SS20.
MATERIALS AND METHODS
Patient selection
A total of 15 patients with primary SS fulfilling the US/European consensus group
classification criteria3  were included upon giving informed consent. Evidence of
sublabial MSG involvement was present in all 15 patients, indicated by a LFS > 1.
An IgA-containing plasma cells percentage (IgA%) < 70,  shown to  be strongly
associated  with  SS4,  was  present  in  all  patients.  Patients  did  not  use
immunosuppressive agents such as corticosteroids or DMARD. 
Table 1. Baseline characteristics of patients with primary SS (n = 15). Values are the number
(%) of patients, except where noted.
Male: Female 1:14
Mean age, yrs (range) 47.9 (21–80)
Mean disease duration, yrs (range) 3.6 (1–10)
Oral symptoms 15 (100)
Ocular symptoms 14 (93)
Other sicca symptoms 15 (100)
Oral signs 15 (100)
Ocular signs 13 (87)
Positive MSG biopsy 15 (100)
Anti-SSA positive 14 (93)
Anti-SSB positive 13 (87)
IgM-RF positive 14 (93)
Hypergammaglobulinemia 11 (73)
Fatigue 15 (100)
Recurrent fever episodes 7 (47)
Arthralgia 12 (80)
Myalgia 8 (53)
MSG: minor salivary glands, at least one positive biopsy (LFS > 1.0 and IgA % < 70). RF:
rheumatoid factor.
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Pilocarpine,  which  potentially  increases  salivary  flow  and  tear  production,  was
taken in a constant dosage throughout the study by one of the 15 participants.
At baseline, patients had to have experience of moderate to severe fatigue, which
was the main outcome measure in this study. Table 1 shows the main baseline
characteristics of all patients.
Intervention with etanercept 
Patients were treated with etanercept in subcutaneous doses of 25 mg twice per
week during 12 weeks of treatment. Followup visits were at 4, 8, and 12 weeks
after the start of treatment, followed by post-treatment followup visits at Weeks 18
and 24.
Measurement  of  fatigue.  Fatigue  was  quantified  throughout  the  study  using  the
Multidimensional  Fatigue Inventory (MFI)  questionnaire.  The MFI  has been validated for
measuring fatigue in Dutch patients with SS6. At each visit the patients completed the MFI
questionnaire and a visual analog scale (VAS) scale for perceived disease activity. The MFI
consists of 20 questions in 5 scales revealing different dimensions of fatigue (i.e., general
fatigue, physical fatigue,  mental  fatigue,  reduced motivation,  and reduced activity).  Each
scale score ranges from 4 to 20, a higher score indicating more severe fatigue21. A clinical
response regarding perceived fatigue was predefined as a decrease of at least 6 points
within a MFI scale [a decrease of 1 point on each item (range 1–5) would decrease a MFI
scale score by 4 points].
Evaluation of salivary and lachrymal gland function 
At baseline and at Weeks 4, 12, and 24 unstimulated and stimulated (2% citric acid)
combined sublingual and submandibular (SL/SM) salivary flow was measured as
recommended by Kalk, et al22. Unstimulated SL/SM flow and stimulated SL/SM flow
was measured for 5 and 10 min, respectively, by manually aspirating saliva with a
Monoject  syringe.  Parotid  flow was blocked using Dry-tips™ absorption shields
covering the opening of  Stensen’s ducts on either side. The weight  of both the
unstimulated and stimulated saliva collecting tubes was electronically measured
before and after collection of saliva, including a third control tube that was not used
for  saliva  collection.  The  latter  enabled  correction  in  case  of  changed
circumstances (such as  room temperature).  At  the same time points  lachrymal
gland function was evaluated using the Schirmer-1 test  (i.e.,  without  anesthetic
droplets  and  with  closed  eyes  for  a  5  min  period).  Complete  ophthalmologic
examination including rose bengal cornea staining and tear film breakup time was
performed at screening and at Week 12 by an ophthalmologist.
Serological and histological evaluation
Serological  tests,  apart  from  standard  safety  tests  and  gammaglobulin  level
measured at each visit, included anti-dsDNA and IgM rheumatoid factor measured
at screening and at Week 12. All serological variables were assessed using routine
standardized  measurement  procedures.  At  baseline  and  at  Week  12  patients
underwent a sublabial MSG biopsy performed by an experienced oral and cranio-
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maxillofacial surgeon. The first biopsy was taken on the left and the second biopsy
on the right side of the lower lip. Focus scores were assessed by an experienced
pathologist, and computer-aided microscopy was used to quantify the IgA%.
Statistical analysis. 
An intention-to-treat (ITT) analysis was performed comparing scores at baseline
and at Week 12. Because MFI scores and VAS scores (Table 2) decreased very
rapidly after cessation of etanercept treatment these scores were compared during
treatment (Week 8) versus baseline scores. Data were analyzed by a paired t test
using the SPSS 9.0 software package.
The pretreatment and post-treatment MSG biopsies (Tables 3 and 4) of  the 10
subjects who underwent both biopsies were also compared using a paired t test. In
this per-protocol statistical analysis one subject was excluded because her MSG
biopsies were assigned the score of 12. Since this is an arbitrarily defined value
describing  a  large  confluent  lymphocytic  infiltrate  that  does  not  enable
measurement of separate lymphocytic aggregates per area, and this value is not
part of a continuous LFS scale, this score was excluded from group comparison.
The post-treatment MSG biopsy of this subject, however,  was again assigned a
LFS of 12 by the pathologist, i.e., no change of the histological picture. Salivary and
lachrymal gland function (Table 5) was not tested statistically because of  extreme
low values in a small study population and no clinical response.
RESULTS
Etanercept  was well tolerated in all  participating patients with  SS. One patient,
however, had to temporarily interrupt etanercept treatment at Week 7 because of a
prolonged  episode  of  parotitis,  which  quickly  resolved  with  antibiotics  after
cessation of etanercept treatment. Due to this interruption, for this patient the data
of subsequent scheduled visits were not acquired at the intended time points. Also,
the parotitis episode considerably biased erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP) values. For this patient it was therefore decided not to
include the data acquired after the treatment interruption in the ITT analysis. Three
other patients ended their participation before completing the protocol due to lack
of efficacy of treatment and were therefore considered as dropouts. Therefore in
the ITT statistical  analysis  the last  observation of  these 4 patients was carried
forward to Week 12.
Systemic signs/symptoms
A persistent decrease of fatigue was reported by 4 of 15 patients, including the
patient who had to temporarily interrupt anti-TNF- treatment due to parotitis. This
was also reflected in the fatigue scores of the MFI and the VAS scores (Table 2,
data of responders described separately at the bottom of the table). For the group
as a whole a statistically significant decrease of the general fatigue scale within the
MFI (p = 0.018) as well as the VAS score for perceived disease activity (p = 0.045)
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was observed. In the clinically responding patients the mean score on the general
fatigue scale diminished from 16.8 to 8.0, and the score on the physical fatigue
scale from 16.2 to 10.0, with the maximum effect reported at Week 8. The effect
started after 2–4 weeks of treatment, and disappeared in 3 patients within 2 weeks
after cessation of etanercept administration. 
Table 2. Multidimensional Fatigue Inventory (MFI) scores. Values are mean (SD).
MFI scales Baseline Week 4 Week 8 Week 12 Week 18 Week 24
Total, n* 15 15 14 12 11 11
General fatigue 16.3 (3.6) 13.9 (3.4) 12.4 (4.7)† 13.1 (3.9) 13.5 (3.7) 13.6 (6.0)
Physical fatigue 15.2 (3.7) 13.2 (3.8) 12.1 (3.2) 13.0 (3.8) 12.5 (4.1) 13.0 (5.5)
Reduced activity 13.0 (3.3) 12.9 (4.4) 12.1 (4.1) 10.3 (3.1) 12.1 (2.9) 12.1 (5.2)
Reduced motivation 11.8 (3.9) 11.1 (3.4) 10.3 (3.2) 10.1 (3.0) 10.5 (3.5) 10.9 (4.7)
Mental fatigue 12.8 (4.4) 11.9 (3.7) 11.3 (4.7) 12.0 (4.5) 10.7 (4.4) 10.3 (4.7)
  VAS, mm 70 (19) 61 (21) 50 (16)† 59 (17) 60 (13) 66 (20)
Responders only
General fatigue 16.8 (3.0) 10.3 (1.5) 8.0 (2.0) 10.0 (3.5) 11.0 (3.6) 14.7 (9.2)
Physical fatigue 16.2 (3.6) 10.0 (2.0) 10.0 (2.6) 10.0 (1.7) 10.0 (4.0) 15.0 (8.7)
Reduced activity 12.8 (3.3) 8.7 (0.6) 11.3 (4.2) 8.0 (1.7) 11.0 (3.6) 13.7 (7.6)
Reduced motivation 10.2 (2.3) 7.0 (2.9) 7.7 (3.5) 8.0 (2.6) 7.3 (3.1) 10.0 (5.6)
Mental fatigue 15.3 (4.4) 13.7 (5.5) 11.7 (4.0) 14.3 (4.6) 11.0 (5.2) 12.3 (4.5)
VAS, mm 73 (16) 41 (20) 34 (10) 53 (22) 67 (14) 67 (32)
* Data of all patients, including the responders. † p < 0.05 vs baseline by paired t test. VAS: Visual analog scale for
perceived disease activity.
Table 3. Serological and histological data. Values are mean (SD).
Baseline Week 4 Week 8 Week 12 Week 18 Week 24
Total, n 15 15 14 12 11 11
ESR, mm 24 (25.6) 24 (26.7) 18 (15.6) 13 (95) 18 (10.5) 20 (11.9)
CRP, mg/l 4.4 (3.8) 4.5 (4.4) 2.8 (1.8) 2.3 (1.6)† 3.2 (1.6) 3.4 (3.3)
Gammaglobulin, g/l 16 (7.1) 17 (8.0) 15 (4.2) 15 (4.8) 15 (4.6) 16 (4.3)
LFS 2.22 (1.5) 1.49 (1.0)
IgA% 56.0 (9.3) 54.3 (8.3)
IgM RF, U/l 85 (95) 80 (102)
Responders only
ESR, mm 19 (18.2) 15 (11.7) 14 (11.9) 12 (12.3) 16 (17.0) 15 (12.2)
  CRP, mg/l 3.7 (2.3) 1.7 (0.6) 2.0 (1.0) 2.0 (1.0) 4.0 (2.8) 2.7 (2.1)
Gammaglobulin, g/l 16 (5.4) 16 (5.4) 15 (6.0) 16 (4.0) 15 (5.9) 18 (0.3)
LFS 2.62 (2.0) 2.08 (0.5)
IgA% 56.1 (16.3) 54.7 (15.6)
IgM RF, U/l 63 (17) 49 (23)
† p < 0.05 versus baseline by paired t test. ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, LFS:
lymphocytic focus score, IgA%: percentage IgA-containing plasma cells, IgM RF: IgM rheumatoid factor.
83
In one patient the effect was prolonged, and disappeared after 8 weeks. In 3 of the
4 responders ESR levels and the IgM rheumatoid factor level decreased during
etanercept treatment. For the entire group the mean ESR decreased from 24 to 13
mm/h (p = 0.058), while the mean CRP values decreased from 4.4 to 2.3 mg/l (p =
0.048), although it should be noted that CRP values in general were already low at
baseline. Gammaglobulin concentrations however were stable throughout the study
in all participants (Table 3). It is noteworthy that one patient appeared to undergo a
“reverse” response: she felt worse during anti-TNF- treatment and much better in
the post-treatment followup phase without treatment. All 15 participants remained
negative for anti-dsDNA antibody throughout the study.
Sicca signs/symptoms
An objective substantial improvement of salivary gland function and improvement
of lachrymal gland function could not be established in any of the 15 patients. Both
Schirmer-1 tests and SL/SM salivary flow measurements showed sustained low to
extremely  low  scores  throughout  the  study  (Table  5).  Also,  no  changes  were
observed in tear film breakup time or rose bengal staining (data not shown).
Subjective  improvement  of  either  irritation  of  eyes  or  dry  mouth  was  also  not
reported in  the majority  of  patients.  One patient  reported less  vaginal  dryness,
leading  to  resolved  dyspareunia  complaints,  and  one  patient  reported  less
respiratory  tract  dryness.  Two  patients  who  frequently  experienced  severe
blepharitis reported considerable alleviation of  eye symptoms during etanercept
treatment. However, once etanercept treatment was stopped, these patients again
encountered ocular discomfort due to blepharitis.
Table 5. Salivary and lachrymal gland function tests. Values are mean (SD).
Baseline Week 4 Week 12 Week 24
Total, n 15 15 12 11
  Schirmer-l, mm/5 min 5.0 (5.8) 5.9 (6.2) 5.8 (7.0) 5.6 (9.8)
U-SL/SM flow, ml/5 min 0.1 < 0.01 < 0.01 < 0.01
S-SL/SM flow, ml/10 min 0.4 0.3 0.4 < 0.01
Responders only
Schirmer-l, mm/5 min 0.3 (0.6) 1.7 (0.6) 2.0 (1.7) 1.3 (1.5)
U-SL/SM flow, ml/5 min < 0.01 < 0.01 < 0.01 < 0.01
S-SL/SM flow, ml/10 min < 0.01 < 0.01 < 0.01 < 0.01
SL: sublingual, SM: submandibular, U: unstimulated, S: stimulated with 2% critic acid once
per 2 minutes.
Pre- and post-treatment salivary gland biopsy scores
The (immuno)histological pattern of the pre- versus post-treatment sublabial MSG
biopsies  interestingly  showed  a  trend  to  decreased  lymphocytic  focus  scores
following etanercept treatment. Only one of 10 samples showed a slightly (0.25)
increased post-treatment LFS, while in 7 of 10 samples a decrease varying from
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0.2 to 2.4 points was observed in the post-treatment LFS (Table 4). However, the
difference in post-treatment LFS (p = 0.101) and IgA% (p = 0.621) from baseline
values was not statistically significant (Table 3).
Thus, the (immuno)histological pattern was compatible with the clinical findings for
sicca signs and symptoms. As well no noteworthy differences were observed in
sublabial  MSG  biopsy  scores  from  patients  with  decreased  fatigue  versus
nonresponding patients. Table 4 shows, surprisingly, that in 3 of 15 subjects a LFS
< 1.0 was found at baseline. In all 3 patients a previous diagnostic MSG biopsy had
shown a LFS > 1.0. Furthermore, in 2 of these 3 patients the IgA% at baseline was
below 70, which has been shown to be a more disease-specific marker4,5. In the
third patient a LFS could not reliably be assessed and IgA% could not be assessed
at all due to a bad sample. The double MSG biopsies were well tolerated in this
study population. One patient complained about postbiopsy  numbness of the lip,
while all other biopsies were taken without complications. Although in 9 of the 15
participants a previous diagnostic lower lip biopsy had preceded the 2 biopsies
taken in this study, no difficulties were encountered assessing LFS and IgA% in the
study samples.
Table 4. Pre- versus post-treatment minor salivary gland (MSG) biopsy scores. (Only the
data of double MSG biopsies are shown).
Patient Time 0 Time 1
LFS IgA% LFS IgA%
1 0.18 60.7 0.22 65.2
2 12 37.1 12 34.4
3 0.5 NA 0.34 62.7
4 3.39 61.0 2.85 54.9
5 4.9 58.2 2.47 65.7
6 1.91 58.4 1.73 59.3
7 2.68 64.0 2.35 48.4
8 1.44 38.8 1.69 43.6
9 0.62 62.5 0.15 49.0
10 2.11 44.2 1.61 48.6
Time 0: pretreatment biopsy, Time 1: post-treatment biopsy, LFS: lymphocytic focus score,
IgA%: percentage IgA-containing plasma cells, NA: data not available (unreliable small
tissue sample).
Extension phase 
After completing the study protocol including the 12 week post-treatment followup
without etanercept, all 4 responding patients resumed etanercept treatment 25 mg
twice a week. Again, fatigue symptoms decreased quickly (within 2–4 weeks), but
as well, after prolonged treatment for up to 26 weeks, no effects on sicca signs or
symptoms were noted. No adverse events occurred in patients who participated in
this extension phase.
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DISCUSSION
In this pilot study, subcutaneous administration of etanercept 25 mg twice weekly in
patients with SS did not improve salivary or lachrymal gland function. However, in a
small subgroup of patients, there was markedly reduced fatigue as well as reduced
ESR level, which may indicate a possible systemic response. This study describes
4 of 15 patients who reported less fatigue during etanercept treatment. Although
fatigue cannot be assessed objectively, and the numbers of participants in this pilot
study were small, their reports were very consistent throughout and following the
study. Fatigue scores worsened again in the post-treatment followup phase of the
protocol,  but  after  restarting etanercept  treatment in the extension phase these
patients again reported a quick decrease of perceived fatigue. In these patients the
(immuno)histological  pattern  in  the  MSG  biopsies  did  not  differ  from  that  of
nonresponders in terms of fatigue. Indeed, although decreased LFS scores were
observed, etanercept treatment did not lead to statistically significant changes in
MSG biopsy scores in any patient in this study. In general, etanercept was well
tolerated  and  appeared to  be a  safe drug  for  patients  with  SS.  These  results
contrast in part to observations of Steinfeld, et al, who reported a beneficial effect
of anti-TNF-  treatment with infliximab on both fatigue complaints and sicca signs
in a very similar open label pilot study18. This might be explained by differences in
patient selection and chosen method of saliva collection, or result from different
efficacy of infliximab versus etanercept in SS.
Although both anti-TNF- agents have potent antiinflammatory effects in RA11,23,
some recent clinical studies in other autoimmune diseases indeed suggest different
clinical  efficacy of  etanercept  compared to infliximab. For example,  the differing
results of initial studies with infliximab and etanercept in Crohn’s disease15,24,25 are
quite  similar  to  our  results  compared  to  those  of  Steinfeld,  et  al  in  SS.  One
hypothesis  drawn  from  an  in  vitro  study  is  that  while  both  antagonists  block
circulating TNF- molecules, the blocking of membrane-bound TNF- lasts longer
in infliximab treatment compared to etanercept  treatment,  in which the receptor
fusion protein appears to dissociate from the membrane-bound TNF- some time
after having bound to it26. As a consequence, a higher etanercept dosing regimen,
or  shorter  dosing interval,  might  be needed  to  achieve  comparable efficacy  to
infliximab  in  SS.  Although  the  exact  characterization  of  systemic  signs  and
symptoms in patients with SS is unknown, it is noteworthy in this respect that a
subgroup of patients reported less fatigue during etanercept treatment yet none of
these  patients  showed  functional  improvement  of  the  glands.  However,  since
measuring serum concentrations of TNF- was not part of the study design, the
hypothesis that circulating TNF- levels might be associated to fatigue cannot be
verified in this study. For efficacy of  anti-TNF- treatment in SS, careful  patient
selection  may  be  important  as  well,  since  reversibility  of  decreased  glandular
function in an advanced stage of the disease is questionable. To compensate for
this issue in future studies, one might define a minimum glandular rest function at
baseline or challenge patients with pilocarpine to test for potential reversibility of
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glandular  function.  This  might  increase the probability  of  successful  etanercept
intervention resulting in a functional response of the glands. Measuring parotid flow
next to sublingual and submandibular flow might have given additional information
about the functional status of salivary glands. However, from the evidence that the
majority of patients did not  report  improvement of  dry mouth, and macroscopic
inspection of the absorption shields that were used to block parotid flow into the
oral cavity did not show improvement as well, it is unlikely that a clinically important
improvement of salivary flow was overlooked by not measuring parotid flow.
In  conclusion,  etanercept  administered  subcutaneously  in  a  conventional  RA
dosing regimen of 25 mg twice weekly did not lead to improvement of sicca signs
and symptoms in 15 patients with primary SS. In a small subgroup of patients,
however, a presumed systemic response was observed, indicated by a reduction of
moderate to  severe  fatigue complaints  in  these  patients.  Since  this  etanercept
dosing  regimen  did  not  result  in  statistically  significant  histological  changes  in
sublabial MSG gland biopsies,  there are no indications that  diagnostic biopsies
taken,  for  example,  in  patients  with  RA are  biased  by  concomitant  etanercept
treatment.  Additional  studies  might  elucidate  the  possible  fatiguereducing
mechanism  of  anti-TNF- treatment.  The  efficacy  of  etanercept  treatment  in
reducing oral and ocular dryness in SS should be evaluated in studies with a higher
dosage or shorter dosing intervals.
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CHAPTER 8
Summary
Sjögren’s  syndrome  (SS)  is  considered  a  chronic  autoimmune  exocrinopathy,
predominantly involving salivary and lacrimal glands. Exocrine glands that are located
in the upper airways, the vagina and possibly the skin may also be affected. As a
result  of  exocrinopathy  the  clinical  manifestations  of  SS  typically  include  sicca
symptoms such as dry eyes and dry mouth. In addition the syndrome is clinically
characterised by non-specific flu-like symptoms such as fever, arthralgia, myalgia and
fatigue. SS is thought to affect approximately 0.5-1.0% of the population in the US and
Europe, and has been subject of extensive scientific research. One of the continuing
dilemmas in both research and daily clinical practice however is how to define SS. As
a consequence, data obtained can often not be easily compared. Importantly, in daily
clinical practice some physicians diagnose SS by using classification criteria sets,
whereas others prefer to establish a diagnosis based on the clinical symptoms and
signs that constitute the syndrome originally described by Henrik Sjögren, a Swedish
ophthalmologist. 
A general  introduction  to  this  thesis  is  provided in  Chapter  1. In  this  chapter  a
historical overview of the evolving concept of SS, starting from the early descriptions
of the syndrome by Henrik Sjögren and others, followed by a description of various
proposed classification criteria and consecutive modifications that have been applied
to them, is given. Difficulties that are currently encountered in the development of an
objective  diagnostic  model  and  disease  activity  measurement  tool  for  SS  are
discussed here and provide the background for this thesis.
In the current 2002 American/European Consensus Group (AECG) classification
criteria for SS objective items, such as serum presence of anti-SS-A and anti-SS-B
antibodies (anti-SS-A, anti-SS-B),  are emphasized.  In  the sera of  approximately
20% of  SS patients  no  anti-SS-A or  anti-SS-B can  be  detected  at  the  time  of
diagnosis.  However,  in  these  ‘seronegative’  patients  anti-SS-A or  anti-SS-B may
nevertheless be present in other body compartments, e.g. within the exocrine glands
or their  excreta such as tear fluid  or saliva.  Chapter  2  describes a study that  is
focussed  on  the  relatively  understudied  group  of  anti-SS-A  and  anti-SS-B
seronegative SS patients. The aims of this study were to assess whether anti-SS-A
and anti-SS-B could be detected in tear fluid samples of our seronegative SS patient
population, and to examine whether seroconversion to a positive profile occurred after
disease had progressed for at least five years since diagnosis. If either of these was
the case, the  “intrinsic” disease-sensitivity of anti-SS-A and anti-SS-B could be higher
than previously assumed. The results of this study show that there are no indications
for seroconversion over time from an anti-SS-A and anti-SS-B negative to positive
serological profile in  patients previously tested seronegative. However, in  some of
these seronegative patients anti-SS-A presence can be found in tear fluid samples. In
seropositive patients that served as controls both anti-SS-A and anti-SS-B presence
was  demonstrated  in  tear  fluid  samples.  A  remarkably  low  amount  of  tear  fluid
(approximately 5 8l) appeared to be enough to detect anti-SS-A by ELISA. However,
the number of examined seronegative tear fluid samples was small, and measured
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sensitivity was low. Thus,  tear fluid analysis for presence of anti-SS-A or anti-SS-B in
seronegative SS patients has yet to prove its additional diagnostic value.
Implications from this study in clinical practice are:
1. Repeated serological analysis for anti-SS-A or anti-SS-B presence in previously 
known seronegative patients is of no additional diagnostic value.
2. Although  optimised  tear  fluid  analysis  might  reveal  anti-SS-A  or  anti-SS-B  
presence  in  seronegative  SS  patients,  thereby  facilitating  the  diagnosis  of  
Sjögren’s syndrome, the yield of tear fluid analysis in these patients is currently 
too low to be advocated in clinical practice
The disease sensitivity of anti-SS-A and anti-SS-B has been reported to be 60-75 %
and 30-50 % respectively, whereas disease specificity of particularly anti-SS-B is
generally considered as reasonably high. Anti-SS-B is mostly found in SS and SLE
patients, and rarely present in other diseases or normal healthy subjects (NHS).
However,  as  mentioned  above,  approximately  20% of  SS  patients  lack  serum
presence of anti-SS-A and anti-SS-B. Because of this limited disease sensitivity and
specificity, the search for an autoantibody showing a better disease sensitivity and
specificity profile continues. Anti-alpha-fodrin autoantibodies (anti-alpha-fodrin) are
amongst  the  proposed  candidate  serological  markers  for  SS.  Previously  the
disease sensitivity and specificity profile of anti-alpha-fodrin has been claimed to be
superior to that of anti-SS-A and anti-SS-B. From initial studies a disease sensitivity
of 96% was reported for anti-alpha-fodrin in primary SS, whilst disease specificity
of  these  antibodies  was  comparable  to  that  of  anti-SS-B.  However,  the  data
presented  in  Chapter  3 show  that  the  previously  reported  superior  disease
sensitivity and specificity profile of anti-alpha-fodrin could not be reproduced in our
cohort of well-defined SS patients. 
This was concluded based on multiple ELISA measurements that were combined
with  at  least  one alternative biochemical  technique for  confirmation of  obtained
data. In contrast to anti-alpha-fodrin, all anti-SS-A and anti-SS-B activities detected
in  our  sera  by  ELISA  could  be  confirmed  by  using  alternative  biochemical
techniques. Also, in this study the observed sensitivity of  anti-SS-A and anti-SS-B
was  higher  than  that  of  anti-alpha-fodrin.  In  addition,  a  considerable  overlap
between the presence of anti-SS-A, anti-SS-B and anti-alpha-fodrin was observed.
A  potential  contributing  role  for  anti-alpha-fodrin  measurement  to  detect  SS
patients that are negative for anti-SS-A and anti-SS-B appears therefore unlikely. In
addition, although this study was not designed to evaluate the disease specificity of
anti-alpha-fodrin, it is unlikely to exceed that of anti-SS-B considering the detection
of some anti-alpha-fodrin positive sera in rheumatoid arthritis  (RA) patients.
 
Therefore, in clinical practice, the measurement of anti-alpha-fodrin autoantibodies
does not add much to the diagnosis of Sjögren’s syndrome.
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In  view of  the current  concept  of  Sjögren’s  syndrome (SS)  as an autoimmune
exocrinopathy of unknown origin, xerosis (dry skin), which is frequently reported in
SS,  has  been  assumed  to  result  from  cutaneous  exocrinopathy.  However,
convincing histological evidence for this hypothesis is lacking. Theoretically, if the
typical  infiltrating lymphocyte aggregates, such as seen in  biopsy specimens of
salivary glands, could also be found in skin tissue, a diagnostic skin biopsy could
serve as an alternative to salivary gland tissue biopsy in SS patients. Exocrine
glands  in  the  human  skin  include  sebaceous  glands  as  well  as  eccrine  or
merocrine (formerly  known as apocrine)  sweat glands.  The sebum, rather than
sweat,  controls  moisture  loss  from the  epidermis.  Decreased  sebaceous gland
function is therefore reflected in xerosis. Interestingly all exocrine glands in human
skin  are under  the control  of  sex  hormones.  Although SS predominantly affects
women,  no  direct  estrogen  mediated  pathophysiological  mechanisms have  been
identified in previous studies. In  Chapter 4 skin biopsy specimens of SS patients
are explored for signs of exocrinopathy. The estrogen-alpha (ER) and estrogen-
beta (ERß) receptor expression in skin and salivary gland biopsies of SS patients
compared to NHS, are also described in this chapter. Evidence for inflammatory
cutaneous exocrinopathy in SS was not found. 
Thus, in clinical practice, a skin biopsy –as an alternative for salivary gland biopsy- is
of no use in the diagnosis of Sjögren’s syndrome. 
In SS patients ERß is the predominant ER in skin and salivary gland tissue. This is
in line with the previously described predominance of ERß in skin and salivary glands
of NHS.  The observed differentiated  ERß expression and the presence of  ERß
positive lymphocytes within salivary gland infiltrates in SS patients may reflect a
role for  ERß in the pathogenesis or maintenance of SS. However, further studies
should point out whether these observations are of pathophysiological relevance. If
so, new pathophysiological and therapeutic concepts for SS may be developed.
Not only the presence of anti-SS-A and anti-SS-B but also a positive salivary gland
biopsy is an objective item emphasised in the AECG criteria. A salivary gland biopsy
is currently considered positive when the lymphocyte focus score (LFS) is greater
than, or equals 1. The LFS represents the number of  mononuclear cell  infiltrates
containing at least 50 inflammatory cells per 4 mm2. However, the limited disease
sensitivity and specificity of the LFS is well known. Therefore, additional examination
of salivary gland tissue might help to differentiate between true- and false positive
and negative LFS. One of the methods to do so is quantitative immunohistological
(QIH)  examination  of  the  salivary  gland  biopsy.  Here  the  composition  of  the
infiltrate is described in terms of  immunoglobulin  subtypes  (IgG,  IgM,  and IgA)
containing cells.  In  the QIH criterion introduced in  1982 by  Bodeutsch et  al.  a
percentage IgA containing plasma cells (IgA%) less than 70 was very specific for
SS. With the QIH criterion some patients previously not fulfilling the classification
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criteria for SS because of a LFS < 1 could be identified as having SS. Furthermore,
auto-immune disease (such as RA) patients with  a LFS>1 (i.e. sialadenitis) but
without any signs or symptoms of SS have been described previously, and often
fail  to  meet  the  QIH  criterion.  Thus,  examining  salivary  gland  tissue  biopsies
immunohistochemically instead of or next to histologically appears favourable. 
In  Chapter 5 the disease-sensitivity and –specificity of histological (LFS) versus
immunohistological (IgA%) results of  salivary gland biopsy are evaluated. In the
majority of cases assessment of  both focus-score and IgA% score leads to an
unambiguous  histological  conclusion.  However,  whether  histological  and
immunohistological findings match or not, neither of them have been shown to be
100% sensitive and specific,  as was also depicted in an analysis of  concordant
biopsies.  In  11% of  cases the conclusion of  histological examination of  salivary
gland biopsies (LFS) did not match with the immunohistological result (IgA%). In
these so called “mismatch” cases the IgA% appears superior to  the LFS when
objective,  serological  findings  are  taken  into  account.  Differentiation  between
sialadenitis  secondary  to  RA  versus  Sjögren’s  syndrome  was  enhanced  by
attributing more value to elevated gammaglobulin-level and presence of anti-SS-A
and anti-SS-B. These parameters appear to be more Sjögren’s syndrome-specific
objective parameters than rheumatoid factor and ANA, which are also frequently
present in e.g. RA patients.
Our  data  suggest  that  in  clinical  practice the  accuracy  of  diagnosis  can  be
enhanced if  both LFS and IgA% score of  salivary gland biopsy  are taken into
account.   In  cases  of  doubt,  the other  parameter  can direct  towards the right
diagnosis. In this study the number of false negative IgA% scores was remarkably
low. An IgA% >70 combined with a LFS >1 should therefore be interpreted as a
false positive LFS. The interpretation of a LFS <1 in combination with an IgA% <70
is less clear, since both false negative LFS and false positive IgA% scores occur
with equal frequencies.
Although no effective systemic treatment for SS is available to date it should be
noted that in clinical trials treatment efficacy is mainly clinically evaluated using a
wide range  of  non-uniform objective and subjective  parameters.  A need for an
objective disease activity parameter is widely felt. 
Reversibility is an important  component of  the currently proposed disease activity
model. However, well-documented clinical or histological reversibility has not been
reported in SS studies. In Chapter 6 the results of (immuno)histological examination
of salivary gland tissue before and after treatment with high dose corticosteroids in a
SS  patient  are  described.  Both  LFS  and  IgA% were  suggestive  for  SS  before
treatment,  and  normalised  after  treatment.  This  case  suggests  that
(immuno)histological  changes in  SS might  be reversible.  Thus,  repeated salivary
gland biopsy may offer an objective tool in evaluating efficacy in therapeutic trials.
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Although this observation comes from a single case report,  in clinical practice it
should be taken into account that false-negative (immuno)histological results from
salivary  gland  biopsies  can  occur  in  case  of  concomitant  corticosteroids
medication.
In order to further explore the potential reversibility of immunohistological changes in
salivary gland biopsies, and to evaluate clinical efficacy, a pilot study in which SS
patients  were  treated  with  etanercept  (Enbrel®),  was  performed  (Chapter  7).
Etanercept  (Enbrel® ),  a  soluble  fully  human  TNF- -p75-receptor  fusion  protein,
interferes  with  the  inflammatory  process  by  binding  and  inactivating  the  pro-
inflammatory cytokine TNF- . Since enhanced TNF-  expression has been observed
in  exocrine  glands  of  patients  with  SS,  anti-TNF-  treatment  might  potentially
suppress inflammation in SS with local and systemic effects. However, from the data
obtained  from  this  pilot  study  it  was  concluded  that  etanercept,  administered
subcutaneously in a conventional RA dosing regimen of 25 mg twice weekly, did not
lead to improvement of sicca signs and symptoms in 15 SS patients. Furthermore, this
etanercept dosing regimen did not result in statistically significant histological changes
in salivary gland biopsies. Thus, in contrast to corticosteroids treatment,, there are no
indications that diagnostic salivary gland biopsies results are biased by concomitant
etanercept treatment.  
In clinical practice, etanercept in a dosing regimen of 25 mg twice weekly, does not
offer an effective treatment modality for SS.  From a diagnostic  point-of-view, it
appears that salivary gland biopsies results are not biased by concomitant etanercept
treatment.
Concluding remarks
The various components of this thesis can all be considered in the context of the
evolving concept of SS in which the focus is currently on improvement of the existing
classification criteria and the development of a disease activity measurement tool. In
the most recent  modification of  SS classification criteria,  the 2002 AECG criteria,
objective signs, i.e. the presence of anti-SS-A or anti-SS-B and a positive salivary
gland biopsy, are emphasised. However, both objective signs are limited in disease
specificity as well as disease sensitivity. Thus, the further development of classification
criteria showing a better  performance on disease specificity and sensitivity is  still
much needed. In this thesis both the serological and the histological item within the
current  classification  criteria  were  subject  of  further  evaluation.  Anti-alpha  fodrin
antibodies could not be shown to be superior to anti-SS-A and anti-SS-B, and should
therefore not  substitute  anti-SS-A and  anti-SS-B presence  in  the current  criteria.
Meanwhile the disease sensitivity and specificity of anti-SS-A and anti-SS-B remains
limited.  Approximately  20  percent  of  SS  patients  lack  serum  presence  of  these
antibodies and continue to do so as disease progresses. Although these antibodies
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can also be detected in the saliva and tear fluid of SS patients, it is questionable
whether  analysis  of  these  exocrine glands  excreta  will  considerably  improve  the
disease sensitivity of these antibodies. A positive salivary gland biopsy is currently
defined by a minimum LFS of 1. However, numerous previous studies have shown
that both disease specificity as well as disease sensitivity performance of the LFS as
histological parameter is poor. One way of improving the disease specificity of salivary
gland biopsy  may be found in  analysis of  the composition of the salivary gland
infiltrates, e.g. by measurement of the percentage IgA containing plasmacells. The
combination of IgA% and LFS was shown to increase the accuracy of diagnosis in
SS. 
A disease activity model for SS is currently under development.  Reversibility is an
important feature of the proposed model. However, reversibility has not often been
objectively documented in SS. Considering the mild, slowly progressing course of
disease, and the low rate of patient-reported flares, the actual presence of measurable
disease activity in SS is questionable. This may be due to the fact that when SS
becomes clinical manifest and diagnosed, patients are apparently in a late stage of
disease,  with  little  opportunities  for  reversibility  of  already  present  exocrinopathy.
Defining a disease severity (or  damage)  index to start with may be more suitable
given the stable clinical course observed in SS. However, so far only a single study of
end-organ damage has been performed in SS patients.
In order to diagnose the syndrome before irreversible glandular damage occurs, a
screening test for SS will have to be considered in a “pre-sicca” stadium in which the
patient may only present with non-specific symptoms. This demands a quick, cheap
and preferably non-invasive screening test to rule out or confirm SS in potentially large
numbers of patients. However, the need for early diagnosis before irreversible damage
has taken place, may not be widely felt  before a curative treatment, that  enables
intervention in the course of Sjögren’s syndrome, is found.
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CHAPTER 9
Samenvatting
Het syndroom van Sjögren (SS) wordt beschouwd als een chronische auto-immuun
aandoening van exocriene klieren,  zich met name manifesterend in  speeksel-  en
traanklieren.  Tevens  kunnen  exocriene  klieren  gelokaliseerd  in  de  bovenste
luchtwegen, vagina en mogelijk ook in de huid, betrokken zijn bij deze exocrinopathie.
De klinische verschijnselen van SS vloeien voort uit de onderliggende exocrinopathie
en omvatten o.a. typische sicca symptomen als droge ogen en een droge mond.
Daarnaast  wordt  SS klinisch  gekarakteriseerd  door  niet-specifieke  “griep-achtige”
verschijnselen  zoals  koorts,  gewrichtspijn,  spierpijn  en  vermoeidheid.  Er  wordt
geschat dat SS aanwezig is in circa 0.5-1.0% van de bevolking in de USA en Europa,
en  het  ziektebeeld  is  reeds  onderwerp  geweest  van uitgebreid  wetenschappelijk
onderzoek. Eén van de continu aanwezige dilemma’s zowel bij onderzoek als in de
dagelijkse klinische praktijk, is hoe het SS gedefinieerd moet worden. Dientengevolge
kunnen  resultaten verkregen bij  onderzoek niet  eenvoudig met elkaar  vergeleken
worden. Van belang is tevens dat in de dagelijkse klinische praktijk SS door sommige
artsen gediagnosticeerd wordt aan de hand van classificatie criteria, terwijl  andere
artsen  er  de  voorkeur  aan  geven  SS  te  diagnosticeren  op  basis  van  klinische
verschijnselen die onderdeel vormen van het syndroom dat oorspronkelijk beschreven
is door Henrik Sjögren, een Zweedse oogarts. 
Een algemene inleiding op dit  proefschrift  wordt  in  Hoofdstuk 1  gegeven. In  dit
hoofdstuk wordt een historisch overzicht gegeven van het zich in de tijd ontwikkelende
concept van SS, startend met de eerste beschrijvingen van het syndroom door Henrik
Sjögren  en  anderen,  gevolgd  door  een  beschrijving  van  diverse  voorgestelde
classificatie criteria en opeenvolgende modificaties hier aan. De problemen die op dit
moment ondervonden worden bij het ontwikkelen van een objectief model voor de
diagnose van SS en het bepalen van de ziekte-activiteit in SS worden tevens in dit
hoofdstuk besproken en vormen de achtergrond voor dit proefschrift.
In  de huidige  2002  American/European Consensus Group (AECG) classificatie
criteria voor SS worden objectieve items, zoals de aanwezigheid van anti-SS-A of
anti-SS-B antistoffen (anti-SS-A, anti-SS-B) in het serum, benadrukt. In het serum
van  circa  20%  van  de  SS  patiënten  wordt  echter  geen  anti-SS-A  of  anti-SS-B
gedetecteerd op het moment van het stellen van de dignose. In deze ‘seronegatieve’
patiënten kan anti-SS-A of anti-SS-B niettemin elders in het lichaam aanwezig zijn, bv.
in de exocriene klieren zelf of in hun excreta als traanvocht of speeksel. In Hoofdstuk
2 wordt een studie beschreven welke gericht is op deze relatief weinig bestudeerde
groep van anti-SS-A en anti-SS-B seronegatieve SS patiënten. Het doel van deze
studie was om vast te stellen of anti-SS-A en anti-SS-B gedetecteerd zouden kunnen
worden in traanvochtmonsters van onze seronegatieve SS patiënten populatie, en om
na te gaan of seroconversie naar een positief serologisch profiel optreedt als de ziekte
minimaal vijf jaar voortgeschreden is sinds het stellen van de diagnose. Als één van
beiden het geval blijkt te zijn dan zou de “intrinsieke” sensitiviteit van anti-SS-A en
anti-SS-B hoger kunnen zijn dan tot nu toe is aangenomen. De resultaten van deze
studie tonen dat er geen aanwijzigen zijn dat seroconversie van een negatief naar
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positief anti- SS-A en anti-SS-B  serologisch profie plaatsvindt in het beloop van SS.
Wel is gebleken dat in sommige seronegatieve SS patiënten anti-SS-A aanwezigheid
wel kan worden aangetroffen in traanvochtmonsters. In seropositieve SS patiënten die
als controle dienden werd zowel anti-SS-A als anti-SS-B aanwezigheid aangetoond in
traanvochtmonsters. Een opmerkelijk klein volume aan traanvocht (circa 5 8l) bleek
reeds voldoende te zijn om deze antistoffen te kunnen aantonen met behulp van
ELISA.  Daarbij  dient  wel  aangetekend  te  worden  dat  het  aantal  onderzochte
seronegatieve patiënten klein was en de gemeten sensitiviteit eveneens laag was. De
toegevoegde diagnostische waarde van traanvocht analyse op aanwezigheid van anti-
SS-A of  anti-SS-B in  seronegatieve SS patiënten dient  derhalve nog bewezen te
worden.
Implicaties van deze studie voor de klinische praktijk zijn:
• Herhaald serologisch onderzoek op de aanwezigheid van anti-SS-A of anti-SS-B
in  voorheen  seronegatieve  patiënten  heeft  geen  toegevoegde  diagnostische
waarde.
• Hoewel  geoptimaliseerde  traanvocht  analyse  anti-SS-A  of  anti-SS-B
aanwezigheid  kan  onthullen  in  seronegatieve  SS  patiënten,  daarmee  het
diagnosticeren van SS faciliterend, is de opbrengst van traanvocht analyse in
deze patiënten thans te laag om aan te bevelen in de klinische praktijk
De eerder gerapporteerde ziekte-sensitiviteit van anti-SS-A en anti-SS-B bedraagt
respectievelijk 60-75 % en 30-50 %, terwijl  de ziekte-specificiteit van met name
anti-SS-B algemeen als zijnde tamelijk hoog beschouwd wordt. Anti-SS-B wordt
voornamelijk  aangetroffen  in  SS  en  SLE  patiënten,  en  is  zelden  aanwezig  in
andere ziekten of  in  de normale gezonde populatie.  Niettemin,  zoals hierboven
reeds gemeld, ontbreekt in circa 20% van de SS patiënten serum aanwezigheid
van  anti-SS-A  en  anti-SS-B.  In  verband  met  deze  beperkte  sensitiviteit  en
specificiteit,  wordt  de  zoektocht  naar  antistoffen  met  een beter  sensitiviteit-  en
specificiteit profiel voortgezet. Anti-alpha-fodrine autoantistoffen (anti-alpha-fodrine)
als serologische marker voor SS vormen één van de voorgestelde kandidaten. Van
het sensitiviteit- en specificiteit profiel van anti-alpha-fodrine is eerder geclaimd dat
het superieur zou zijn aan dat van  anti-SS-A en anti-SS-B. In de oorspronkelijke
studies werd een sensitiviteit van 96% gerapporteerd van anti-alpha-fodrine in het
primaire SS, terwijl de specificiteit vergelijkbaar zou zijn met die van anti-SS-B. De
resultaten  gepresenteerd  in  Hoofdstuk  3 laten  echter  zien  dat  de  voorheen
gerapporteerde  sensitiviteit  en  specificiteit  van  anti-alpha-fodrine  niet
gereproduceerd  konden  worden  in  ons  cohort  van  goed  gedefinieerde  SS
patiënten. Deze conclusie is gebaseerd op meerdere ELISA metingen welke met
minimal  één  alternatieve  biochemische  meettechniek  bevestigd  werden.  In
tegenstelling tot  anti-alpha-fodrine,  konden alle  anti-SS-A en anti-SS-B positieve
sera in de ELISA bevestigd worden d.m.v. alternatieve biochemische technieken.
Voorts was de geobserveerde sensitiviteit en specificiteit van anti-SS-A en anti-SS-
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B hoger dan die van anti-alpha-fodrine. Bovendien bleek een aanzienlijke overlap
te  bestaan tussen  aanwezigheid  van  anti-SS-A, anti-SS-B en  anti-alpha-fodrine
antistoffen. Een potentieel bijdragende rol van anti-alpha-fodrine bepaling om SS
patiënten te detecteren die  anti-SS-A en anti-SS-B seronegatief zijn, lijkt daarom
onwaarschijnlijk. Hoewel het studiemodel niet gericht was op het vaststellen van
ziekte specificiteit lijkt het voorts onwaarschijnlijk dat de specificiteit van anti-alpha-
fodrine die van anti-SS-B overstijgt, gezien de detectie van enkele anti-alpha-fodrine
positieve sera in reumatoïde artritis  (RA) patiënten.
 
Het bepalen van anti-alpha-fodrine antistoffen voegt derhalve niet veel toe aan de
diagnose van het syndroom van Sjögren.
In het kader van het huidige concept van SS als auto-immuun exocrinopathie van
onbekende origine, wordt verondersteld dat frequent gerapporteerde xerosis (droge
huid) het gevolg is van cutane exocrinopathie. Overtuigend histologisch bewijs voor
deze  hypothese  ontbreekt  echter.  Theoretisch  gezien  zou  een  huidbiopt  als
diagnosticum kunnen dienen als een alternatief voor het lipbiopt mits de typische
infiltrerende lymfocyten aggregaten, die gezien worden in speekselklierbiopten ook
in de huid worden aangetroffen.
Exocriene klieren in de huid omvatten talgklieren en eccriene alsmede merocriene
(voorheen  apocrien  genoemde)  zweetklieren.  Talg  is,  veel  meer  dan  zweet,
betrokken  bij  het  reguleren  van  vochtverlies  uit  de  epidermis.  Een  afgenomen
talgklier  functie  weerspiegelt  zich  dan  ook  in  xerosis.   Interessant  is  dat  alle
exocriene  klieren  in  de  menselijke  huiid  (mede)  gereguleerd  worden  door
geslachtshormonen.  Hoewel  SS  voornamelijk  bij  vrouwen  voorkomt  is  er  tot
dusverre  nimmer  een  direct  door  oestrogenen  gemedieerd  onderliggend
pathofysiologsich  mechanisme  geïdentificeerd.  In  Hoofdstuk  4 worden
huidbiopten van SS patiënten onderzocht op tekenen van exocrinopathie. Tevens
worden in  dit  hoofdstuk  de oestrogeen-alpha (ER)  en  oestrogeen-beta  (ERß)
receptor  expressie  in  huid-  en  speekselklierbiopten  van  SS  patiënten,  in
vergelijking met controle  biopten van gezonde vrijwilligers,  beschreven. Er werd
geen bewijs gevonden voor het bestaan van inflammatoire cutane exocrinopathie in
SS. 
In  de  klinische  praktijk  is  derhalve  geen  rol  weggelegd  voor  een  huidbiopt  als
alternatief voor het lipbiopt bij het diagnosticeren van het syndroom van Sjögren. 
In  SS  patiënten  blijkt  dat  ERß  de  overheersend  aanwezige  ER  in  huid  en
speekselklier weefsel is. Dit komt overeen met de eerder beschreven bevindingen
in huid en speekselklier  weefsel  van gezonde  vrijwilligers. Het  in dit  onderzoek
geobserveerde gedifferentieerde ERß expressie patron en de aanwezigheid van ERß
positieve lymfocyten in de speekselklier infiltraten in SS patiënten zou op een rol
voor  ERß  in  de  pathogenese  of  het  onderhouden  van  SS  kunnen  wijzen.
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Aanvullende  studies  moeten  echter  uitwijzen  of  deze  observatie  van
pathofysiologische  betekenis  is.  Indien  dit  het  geval  is  kunnen  nieuwe
pathofysiologische en therapeutische concepten voor het SS ontwikkeld worden
Naast de aanwezigheid van anti-SS-A of anti-SS-B in sera van patiënten vormt ook
een positief speekselklierbiopt een objectief item waaraan extra gewicht is toegekend
in de  AECG criteria.  Een  speekselklierbiopt  wordt  thans beschouwd als  positief
indien  de lymfocytaire  focus  score (LFS)  groter  dan,  of  gelijk  is  aan 1.  De LFS
representeert  het  aantal  mononucleaire  cel  infiltraten  waarin  minimaal  50
inflammatoire cellen per 4 mm2. aanwezig zijn. De beperkte ziekte sensitiviteit en
specificiteit  van  de  LFS  is  echter  alom  bekend.  Additioneel  onderzoek  van  het
speekselklierbiopt kan daarom helpen te differentiëren tussen ware en valse positieve
of  negatieve  LFS   waarden.  Eén  van  de  methoden  hiervoor  is  kwantitatief
immunohistologisch (KIH) onderzoek van het  speekselklierbiopt.  Hierbij  wordt  de
samenstelling van het infiltraat beschreven naar percentage van immunoglobuline
subtypes (IgG, IgM, en IgA) bevattende cellen. In het KIH criterium, geïntroduceerd
in 1982 door Bodeutsch et al. wordt een percentage IgA bevattende plasma cellen
(IgA%) kleiner dan 70 als zeer specifiek voor SS beschouwd. Met behulp van het
KIH  criterium  konden  enkele  patiënten  die  voorheen  niet  voldeden  aan  de
classificatie  criteria  i.v.m.  een  LFS  <  1  alsnog  geïdentificeerd  worden  als  SS
patiënten.  Daarnaast  zijn  eerder  patiënten  beschreven  met  een  auto-immuun
ziekte zoals RA en een LFS>1 (sialadenitis) maar zonder klinische verschijnselen
van SS, en deze patiënten voldoen vaak niet aan het KIH criterium. Het lijkt dus
aanbevelenswaardig om speekselklierbiopten immunohistologisch te analyseren in
plaats van, of gecombineerd met, histologische evaluatie.
 
In  Hoofdstuk  5 wordt  de  ziekte-sensitiviteit  en  –specificiteit  van  histologische
(LFS)  versus  immunohistologische  (IgA%)  resultaten  van  speekselklierbiopten
geëvalueerd. In een ruime meerderheid van de gevallen blijkt zowel de LFS als het
IgA%  tot dezelfde ondubbelzinnige histologische conclusie te leiden. Niettemin, of
beide parameters nu overeenkomen of niet, geen van beiden heeft een sensitiviteit
of  specificiteit  van  100%,  zoals  ook  naar  voren  komt  uit  een  analyse  van
concordante biopten. In 11% van de gevallen stemde de conclusie van histologisch
onderzoek (LFS) niet overeen met die van immunohistologisch onderzoek (IgA%).
In  deze zogenoemde “mismatch”  gevallen lijkt  het  IgA% superieur aan de LFS
wanneer objectieve, serologische bevindingen in ogenschouw genomen worden.
Differentiatie  tussen  sialadenitis  secundair  aan  RA  versus  Sjögren’s  syndrome
werd  bevorderd  door  meer  waarde  toe  te  kennen  aan  een  verhoogd
gammaglobuline en de aanwezigheid van anti-SS-A en anti-SS-B. Deze objectieve
parameters lijken meer SS-specifiek te zijn dan de reumafactor en ANA, welke ook
frequent aanwezig zijn in bv. RA patiënten.
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Deze resultaten suggereren dat  een accurate diagnose van het  syndroom van
Sjögren in de klinische praktijk bevorderd kan worden door zowel LFS als IgA%
van het speekselklierbiopt in ogenschouw te nemen. In twijfelgevallen kan dan de
tweede parameter naar de juiste diagnose wijzen. In dit onderzoek was het aantal
vals-negatieve IgA% scores opmerkelijk laag. Een IgA% >70 gecombineerd met
een LFS >1 zou daarom uitgelegd moeten worden als een vals-positieve LFS. De
interpretatie van een LFS <1 in gecombineerd met een IgA% <70 is minder helder,
aangezien  zowel  vals-negatieve  LFS  als  vals-positieve  IgA% scores  ongeveer
even frequent voorkomen.
Hoewel  er  momenteel  geen  effectieve  systemische  behandeling  voor  SS
beschikbaar is, moet aangetekend worden dat in klinische trials het therapeutisch
effect vooral klinisch geëvalueerd wordt, waarbij gebruik gemaakt wordt van een
scala aan niet-uniforme objectieve en subjectieve parameters.  De behoefte aan
een objectieve maat voor het meten van ziekte-activiteit is dan ook groot. 
Reversibiliteit is een belangrijke component van het momenteel voorgestelde ziekte-
activiteit  model.  Goed gedocumenteerde  kinische  of  histologische reversibiliteit  is
echter nog niet gerapporteerd in SS onderzoek.
In  Hoofdstuk  6 worden  de  resultaten  beschreven  van  (immuno)histologisch
onderzoek van een speekselklierbiopt van een SS patiënt voor en na behandeling
met een hoge dosering corticosteroiden. Zowel LFS als IgA% waren suggestief voor
SS voor starten van de behandeling, en normaliseerden na behandeling. Deze casus
suggereert  dat (immuno)histologische veranderingen in SS reversibel kunnen zijn.
Een herhaald speekselklierbiopt zou dus een objectief instrument kunnen zijn voor het
evalueren van het therapie effect in klinische trials.
In de klinische praktijk moet er rekening mee gehouden worden dat vals-negatieve
(immuno)histologische  speekselklierbiopt  uitslagen  kunnen  optreden  bij
gelijktijdige behandeling met corticosteroïden.
Om  de  potentiële  reversibiliteit  van  immunohistologische  veranderingen  in
speekselklierbiopten nader te onderzoeken, en de klinische therapeutische effectiviteit
te evalueren, werd een pilot study uitgevoerd waarin SS patiënten werden behandeld
met  etanercept  (Enbrel®)  (Hoofdstuk  7).  Etanercept  (Enbrel®),  een  oplosbare
volledig  humane  TNF--p75-receptor  fusie  proteïne,  interfereert  met  het
ontstekingsproces door  het  pro-inflammatoire  cytokine  TNF-  te  binden  en  te
inactiveren. Omdat  toegenomen TNF- expressie  geobserveerd  is  in  exocriene
klieren van SS patiënten, zou anti-TNF- behandeling in SS patiënten potentie het
ontstekingsproces kunnen onderdrukken met lokale en systemische effecten. Uit de
resultaten van deze pilot study moest echter geconcludeerd worden dat etanercept,
subcutaan toegediend in een conventionele RA dosis van 25 mg tweemaal per week,
niet  heeft  geleid  tot  een afname  van sicca  klachten en  verschijnselen in  de 15
deelnemende SS patiënten. Evenmin resulteerde dit etanercept doseringsschema in
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statistisch significante histologische veranderingen in speekselklierbiopten.
In tegenstelling tot behandeling met corticosteroïden zijn er dus geen aanwijzingen
dat  het  resultaat  van  een  diagnostisch  speekselklierbiopt  verstoord  wordt  door
gelijktijdige behandeling met etanercept.  
In de klinische praktijk biedt etanercept in een doseringsschema van 25 mg tweemaal
per week geen effectieve behandelingsvorm voor het syndroom van Sjögren. Vanuit
diagnostisch oogpunt lijkt gelijktijdige etanercept behandeling niet van invloed te
zijn op de resultaten van het speekselklierbiopt.
Conclusie en afsluitende opmerkingen
De verschillende onderdelen van dit proefschrift kunnen allen gezien worden in de
context van het zich ontwikkelende SS concept, dat thans met name gericht is op het
verbeteren  van  de  bestaande  classificatie  criteria  en  de  ontwikkeling  van  een
objectieve meetinstrument voor ziekte-activiteit. In de meest recente wijziging van de
SS classificatie criteria, de 2002 AECG criteria, wordt extra gewicht toegekend aan
objectieve verschijnselen zoals  aanwezigheid van anti-SS-A of  anti-SS-B en  een
positief  speekselklierbiopt.  Voor  beide  objectieve  parameters  geldt  echter  dat  ze
gelimiteerd zijn in ziekte-specificiteit en ziekte–sensitiviteit. Het verder ontwikkelen van
classificatie  criteria,  welke  een  hogere  mate  van  ziekte-specificiteit  en  ziekte-
sensitiviteit bevatten blijft daarom nodig.
In dit proefschrift werden zowel de serologische als histologische items in de huidige
classificatie  criteria  nader  bestudeerd.  Van  anti-alpha fodrine  antistoffen  kon  niet
worden aangetoond dat ze superieur waren aan anti-SS-A en anti-SS-B. Anti-alpha
fodrine antistoffen zouden de in de huidige classificatie criteria aanwezige anti-SS-A
en  anti-SS-B  dan  ook  niet  moeten  vervangen.  De  ziekte-sensitiviteit  en  ziekte-
specificiteit van anti-SS-A en anti-SS-B blijft echter ook gelimiteerd. In circa 20 procent
van de SS patiënten  zijn deze antistoffen afwezig in het serum, en dat blijft ook zo
naarmate de ziekte voortschrijdt. Hoewel anti-SS-A en anti-SS-B ook gedetecteerd
kunnen worden in speeksel en traanvocht van SS patiënten is het nog maar de vraag
of analyse van deze excreta van exocriene klieren daadwerkelijk zal leiden tot een
hogere ziekte-sensitiviteit van deze antistoffen.
Een positief speekselklierbiopt is thans gedefinieerd als een minimum LFS van 1.
Voorheen werd echter reeds in meerdere studies aangetoond dat zowel de ziekte-
specificiteit als de ziekte-sensitiviteit van de LFS als histologische maat matig is. Een
manier om deze te verbeteren kan gevonden worden door de compositie van het
speekselklier infiltraat nader te evalueren, bv. door het bepalen van het percentage
IgA bevattende plasmacellen. Er werd aangetoond dat het gecombineerd bepalen van
IgA% en LFS tot een meer accurate diagnose van het SS kan leiden. 
Een ziekte-activiteit  model  voor  SS is  thans in  ontwikkeling.  Reversibiliteit is een
belangrijke karakteristiek in het voorgestelde model. Reversibiliteit is echter nog niet
vaak op objectieve wijze gedocumenteerd in SS. Het milde, langzaam progressieve
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karakter van het ziektebeloop in ogenschouw nemend, alsmede de lage frequentie
van door patiënten zelf gerapporteerde  flares (opvlammingen van het ziektebeeld),
doet de vraag rijzen of ziekte-activiteit wel daadwerkelijk meetbaar is in SS. Mogelijk is
een en ander een gevolg van het feit dat wanneer SS klinisch manifest wordt en de
diagnose gesteld wordt patiënten zich reeds in een eindstadium van het ziektebeeld
bevinden met weinig uitzicht op reversibiliteit van reeds aanwezige exocrinopathie.
Het lijkt wellicht meer voor de hand te liggen te starten met het definiëren van een
schade-index waarin de ernst van de ziekte (disease severity of  damage index) tot
uiting wordt gebracht, gegeven het stabiele klinische beloop in SS patiënten. Tot nu
toe  is  er  echter  m.b.t.  eind-orgaan  schade  in  SS  slechts  een  enkele  studie
gerapporteerd.
Teneinde SS te  diagnosticeren voordat irreversibele schade aan exocriene klieren
ontstaat,  zou  een  screenende  test  voor  SS  ontwikkeld  moeten  worden  welke
toegepast kan worden in een “pre-sicca” stadium waarin de patiënt zich nog slechts
met niet-specifieke symptomen presenteert. Dit vraagt om een snelle, goedkope en bij
voorkeur niet-invasieve testmethode om SS uit  te  sluiten danwel aan te  tonen in
potentieel  grote  patiënten  populaties.  Echter,  de  behoefte  aan  vroegdiagnostiek
(voordat irreversibele schade heeft plaatsgevonden) wordt mogelijk niet breed ervaren
totdat een curatieve behandeling, welke het mogelijk maakt te interveniëren in het
beloop  van  het  syndroom  van  Sjögren,  beschikbaar  komt,  Tot  die  tijd  lijkt
vroegdiagnostiek, bij gebrek aan bewezen curatieve therapie, weinig consequenties te
hebben. 
106
APPENDIX
Sjogren's syndrome criteria [letter]
Ann Rheum Dis 2002;61:948-949
In  ARD 6/2002  Manthorpe  comments  on  the  recently  proposed  US-European
classification criteria for Sjögren’s syndrome (SS)1. We would like to address some
of the issues he raises, and add some comments.
Now that  the classification criteria  have evolved from rather subjectively  biased
ones to more objective assessments, it is surprising that the two most disease-
specific objective parameters currently available for SS are subject to considerable
criticism. Of course when serological and histological items are emphasised in the
new SS classification  criteria,  their  individual  disease  sensitivity  and specificity
should always be kept in mind. 
In fact all 6 items that are included in the classification criteria can be subject to
discussion. E.g. the Schirmer-1 test, and unstimulated whole salivary flow test have
also  been  criticised  in  a  number  of  papers2-5,  but  these  items  are  rather
recommended in Manthorpe’s paper.
Regarding  sublabial  salivary  gland  biopsies  (SLGBs)  Manthorpe  expresses  his
concerns about their accuracy referring to one paper in which over 50% change of
diagnosis after second examination of SLGBs is reported. However, the authors
themselves report that not using the focus scoring system was probably the most
important reason for the change of diagnosis on second examination. They did not
conclude that the focus score itself –which is mandatory to fulfil item VI- changed
dramatically upon re-examination of the specimens !
Other ways of bypassing inter-observer variability are also available e.g. measuring
two instead of one parameter (e.g. IgA% and focus score) has a synergistic value
for the accuracy of diagnosis6, and moreover computer-aided scoring methods may
provide  non-observer  dependent  data.  For  measuring  the  IgA%  reliable  and
reproducible  objective  data  from  the  biopsies  are  obtained  by  combining
microscope, computer and calibrated software. These biopsies show what is going
on in the target organs of this disease and may provide early diagnostic markers;
one  should  not  put  them  aside  to  easily.  Manthorpe  also  criticises  the  SS
classification criteria for the interdependent relation between anti-SS-A/anti-SS-B
antibodies (item IV) and the focus score (item VI). They are certainly associated to
each other but why is that a problem ? The world-wide accepted ARA criteria for
rheumatoid arthritis contain interdependent items as well. E.g. positive rheumatoid
factor serology is generally considered as strongly associated with radiological joint
damage. Interdependency can also be found in the ACR classification criteria for
SLE (presence of ANA is a distinct item from presence of anti-dsDNA or anti-Sm,
items 11 and 10 respectively). Furthermore it appears inconsistent that Manthorpe
recommends including the patient’s smoking habits in the SS classification criteria.
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This would introduce an interdependent item as well.  Also the dependency does
not equal  a  one-on-one relation,  i.e.  seronegative patients may have a positive
focus score and vice versa. Especially since numerous reports have shown that the
focus score alone can be false-positive or false-negative7-10, the presence of anti-
SS-A/anti-SS-B antibodies, which are still the most disease specific and sensitive
parameters available, has additional value for the accuracy of diagnosis. Finally, it
has yet to be proven that the suggested new antibodies (anti-fodrin, anti-muscarin)
are more sensitive and disease specific than the existing classic anti-SS-A and
anti-SS-B antibodies. Therefore it is too early to include such items in classification
criteria.  Whilst  our  knowledge  of  Sjögren’s  syndrome  increases,  classification
criteria may develop in a way that enhances early diagnosis of possibly reversible
target organ damage. Therefore not the end-stage symptoms and signs (items I to
III and V) but rather the early target organ histological signs and serological signs
are likely to retain their place in the classification criteria. Therefore, in our view the
US-European consensus group is right to emphasise item IV and VI which should
not be neglected until superior alternatives have been introduced.
MM Zandbelt, MD & FHJ van den Hoogen, MD, PhD
Dept Rheumatology – Radboud University Medical Center Nijmegen,The Netherlands
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